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ENGLISH SUMMARY 
Chronic kidney disease (CKD) is a growing problem across the world. It has a 
potentially long and asymptomatic early stage, increased morbidity and mortality 
during the later stages, and requires invasive and expensive treatment for end-stage 
disease. Diagnosis, currently mainly based upon serum creatinine concentrations, is 
not precise during the early stages, and does not encompass important kidney 
functions. Screening could be cost-effective, at least in specific populations, but 
several gaps present in our understanding of CKD must first be filled. 
Acute respiratory distress syndrome (ARDS) affects the lungs, either after a direct or 
indirect insult, resulting in low blood oxygen concentrations (hypoxaemia). 
Pathological mechanisms are being discovered, but are still not fully understood. The 
syndrome carries a high mortality, clinical recognition is suboptimal, and treatment 
options are limited. Therefore, there are many areas where improvements in 
knowledge could improve patient care. 
Nuclear magnetic resonance (NMR) -based metabolomics combines NMR 
spectroscopy and multivariate analysis to enable simultaneous analysis of multiple 
metabolites in blood, urine, tissues, and other biological samples. By applying these 
methods to samples from a rat model of CKD, and to samples from humans following 
cardiac surgery with the use of cardiopulmonary bypass, differences between cases 
and controls were investigated. 
In the CKD project, NMR spectra revealed striking differences between the CKD 
model and the control group. Multivariate analysis was able to differentiate the 
groups, and quantification of metabolites enabled the investigation of individual 
metabolites. Allantoin was significantly altered in all analysed compartments, whilst 
other significant metabolites included: asparagine, benzoate, citrate, creatine, 
dimethylamine, dimethylglycine, fumarate, guanidinoacetate, hippurate, malate, 
myo-inositol, oxoglutarate, trigonelline and trimethylamine. Many of these are 
known to be affected by CKD, but simultaneous analysis of urine and multiple organs 
is relatively unique, and will hopefully enable pathological mechanisms to be further 
explored in human disease. 
In the ARDS project, 19% of patients suffered severe hypoxaemia and 49% suffered 
mild hypoxaemia. Using blood samples taken 16 hours postoperatively, it was 
possible to predict oxygenation status three days postoperatively. Integration 
identified several metabolites that were significantly different between groups, 
including: amino acids such as glycine, lysine, alanine and phenylalanine; energy 
intermediates such as citrate, pyruvate, acetate, acetoacetate, 3-hydroxybutyrate and 
carnitine; and lipids and lipoproteins. After validation, these findings could help 
v 
target resources to those at high risk of postoperative hypoxaemia, as well as 
suggesting areas for further investigation. 
A third project investigated the effect of repeated NMR acquisition, using serum and 
plasma spectra collected for other studies. Although most repeated acquisitions were 
not significantly different, there was a clear and consistent difference in citrate peaks 
in a few serum spectra. No clear pattern could be discerned in plasma, but accurate 
integration was difficult due to the overlapping anticoagulant peaks. There was also 
a clear decrease in the lipoprotein signal in both repeated serum and plasma samples. 
These changes should be considered when interpreting significant metabolites, and 
also emphasise the importance of validating scientific findings. 
In conclusion, NMR-based metabolomics can contribute much to medical research, 
and potentially improve the diagnosis and treatment of many diseases. However, 
some challenges remain, both technical and statistical, and validation of results is 
extremely important. 
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DANSK RESUME 
Kronisk nyresygdom (CKD) er et voksende globalt problem. CKD har et potentielt 
langt og asymptomatisk tidligt stadie, øget morbiditet og dødelighed i de senere 
stadier, og kræver invasiv og dyr behandling i sidste stadie af sygdommen. 
Diagnosen, i øjeblikket primært baseret på serum kreatinin koncentrationer, er ikke 
præcis i de tidlige stadier, og omfatter ikke vigtige nyrefunktioner. Screening kan 
være omkostningseffektiv, i det mindste i bestemte populationer, men flere huller i 
vores forståelse af CKD skal først udfyldes. 
Akut lungesvigt (ARDS) påvirker lungerne, enten efter direkte eller indirekte skade, 
hvilket resulterer i lave iltkoncentrationer i blodet (hypoxæmi). De patologiske 
mekanismer er ved at blive opklarede, men er stadig ikke fuldt forstået. Syndromet 
er forbundet med en høj dødelighed, klinisk anerkendelse er suboptimal, og 
behandlingsmuligheder er begrænsede. Derfor er der mange områder, hvor bedre 
viden kan forbedre patientbehandlingen. 
Nuklear magnetisk resonans (NMR) -baseret metabolomics kombinerer NMR 
spektroskopi og multivariat analyse for at muliggøre samtidig analyse af flere 
metabolitter i blod, urin, væv og andre biologiske prøver. Ved at anvende disse 
metoder på prøver fra en rottemodel af CKD og på prøver fra mennesker efter 
hjertekirurgi med brug af kardiopulmonal bypass blev forskelle mellem syge og 
kontroller undersøgt. 
I CKD-projektet var der markante forskelle i NMR-spektre mellem CKD-modellen 
og kontrolgruppen. Multivariat analyse var i stand til at differentiere grupperne, og 
kvantificering af metabolitter muliggjorde undersøgelsen af individuelle 
metabolitter. Allantoin blev væsentligt ændret i alle analyserede prøvetyper, mens 
andre signifikante metabolitter omfattede: asparagin, benzoat, citrat, kreatin, 
dimetylamin, dimetylglycin, fumarat, guanidinoacetat, hippurat, malat, myoinositol, 
oxoglutarat, trigonellin og trimetylamin. Mange af disse er allerede kendt for at være 
påvirket af CKD, men samtidig analyse af urin og flere organer er relativt unik, og 
vil forhåbentlig gøre det muligt at undersøge patologiske mekanismer i sygdommen 
hos mennesker yderlige. 
I ARDS-projektet udviklede 19 % af patienterne alvorlig hypoxæmi, mens 49 % 
udviklede mild hypoxæmi. Ved hjælp af blodprøver opsamlet 16 timer postoperativt, 
var det muligt at forudsige iltstatus på tredje postoperative dag. Integration 
identificerede flere metabolitter, der var signifikant forskellige mellem grupper, 
herunder: aminosyrer såsom glycin, lysin, alanin og phenylalanin; mellemprodukter 
i energistofskiftet såsom citrat, pyruvat, acetat, acetoacetat, 3-hydroxybutyrat og 
carnitin; og lipider og lipoproteiner. Efter validering kan disse resultater hjælpe med 
vii 
at målrette ressourcerne mod dem, der har høj risiko for postoperativ hypoxæmi, samt 
foreslå områder, der kan undersøges nærmere. 
Et tredje projekt undersøgte effekten af gentagne NMR analyser ved hjælp af serum- 
og plasmaspektre indsamlet til andre undersøgelser. Selv om de fleste gentagne 
analyser ikke var signifikant forskellige, var der en klar og konsekvent ændring i 
citrattoppe i nogle få serumspektre. Der kunne ikke skelnes noget klart mønster i 
plasma, men nøjagtig integration var vanskelig på grund af de overlappende 
antikoagulerende toppe. Der var også et klart fald i lipoproteinsignalet i både 
gentagne serum- og plasmaprøver. Disse ændringer bør tages i betragtning ved 
fortolkningen af signifikante metabolitter, og der understreges betydningen af 
validering af videnskabelige resultater. 
Afslutningsvis, NMR-baserede metabolomics kan bidrage meget til medicinsk 
forskning, og potentielt forbedre diagnosticering og behandling af mange sygdomme. 
Der er imidlertid stadig udfordringer, både tekniske og statistiske, og validering af 
resultater er yderst vigtig. 
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“when a man is capable of being in uncertainties, mysteries, doubts, 
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CHAPTER 1. INTRODUCTION 
1.1. CHRONIC KIDNEY DISEASE (CKD) 
1.1.1. BACKGROUND 
Kidney disease has a long history, reaching back thousands of years. Uroscopy, visual 
examination of the urine, has evolved into modern clinical urinalysis, but there are 
still common features. Proteinuria, for example, was the probable cause of bubbles 
in urine described by Hippocrates (Diamantis et al., 2008), and proteinuria has come 
into focus again as an important biomarker in chronic kidney disease (Klahr et al., 
1994). Diabetes was one of the first diseases described and is referred to in an 
Egyptian manuscript as, “too great emptying of the urine,” whilst “honey urine,” 
which would attract ants, was likely to be a description of diabetes mellitus from 
ancient India (Sanders, 2002). Aristotle suggested that the kidney had two functions: 
to separate surplus liquid from the blood, and to modify this liquid, which will 
eventually be eliminated (Marandola et al., 1994). There was a long period of 
uncertainty about whether the mechanism for urine production in the glomerulus was 
filtration or secretion, and this was only conclusively resolved in 1924 (Jamison, 
2014). However, the functions of the sections of the kidney after the glomerulus have 
been more difficult to investigate. Research has been limited because of less focus on 
these processes, and their importance has only recently been rediscovered 
(Lowenstein and Grantham, 2016). 
 
1.1.2. IMPACT OF CKD 
Chronic kidney disease (CKD) is a global problem, with an increasing cost to society 
(GBD 2016 Causes of Death Collaborators, 2017). The prevalence varies by country 
in Europe, between 3% and 17% (Brück et al., 2016), and the global incidence and 
prevalence have both been increasing, again with marked differences across countries 
(Xie et al., 2018). In addition, the numbers surviving to end-stage renal disease 
(ESRD) and requiring life prolonging but costly dialysis or transplant, are also 
increasing. The problems associated with CKD are also expected to affect low-
income countries disproportionately in the near future, and the costs of dialysis, 
which are already a burden in the USA and Europe, cannot be borne by these 
countries or the affected individuals (Liyanage et al., 2015). 
The two systemic diseases, diabetes mellitus and hypertension, are the most common 
causes of CKD. The global prevalence of both conditions is increasing and, together 
with ageing populations, is driving the increases in CKD (Xie et al., 2018). Diabetes, 
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hypertension and CKD itself can be asymptomatic in the early stages, and even when 
they are treated renal function can still deteriorate slowly. This inexorable decline of 
kidney function is known as CKD progression. Therefore, early diagnosis could help 
immensely, by enabling early treatment of the underlying cause, preventing further 
damage to the kidneys, and because early intervention can reduce the rate of 
functional decline and therefore delay ESRD (Figure 1). 
Although the mechanisms are still not fully elucidated, the effects of CKD are clear 
and include an increased risk of other diseases. The major consequence of CKD is 
cardiovascular disease, with an increased risk even in the early stages of CKD (Levey 
et al., 2011), whilst the risks of cancer are also increased (Stengel, 2010). Problems 
directly related to the deterioration of the physiological functions of the kidney, 
which generally manifest themselves in later disease, include: acidosis, as the kidney 
is unable to excrete excess acid; mineral and bone disorder, as the kidney is unable 
to produce the hormone calcitriol (activated vitamin D) and remove excess 
phosphorus from the blood; sodium and volume overload, due to problems excreting 
sodium; high potassium levels, as the kidney loses the ability to regulate potassium 
concentrations; high blood pressure, due to volume overload and renin production; 
and anaemia due to reduced production of the hormone erythropoietin. 
 
Figure 1. The decline of kidney function with and without treatment. Early diagnosis can 
potentially slow decline and therefore delay end stage renal disease. GFR, glomerular 
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1.1.3. TREATMENT OF CKD 
Once CKD has been diagnosed, treatment consists of finding and removing reversible 
causes, trying to slow progression, and minimising and treating complications. As 
mentioned earlier, high blood pressure and diabetes are the biggest risk factors for 
CKD, whilst cardiovascular disease is the largest cause of death in CKD. Therefore, 
controlling cardiovascular risk factors is of the utmost importance. This involves 
blood pressure control, antiplatelet agents and statins, as well as lifestyle changes 
such as smoking cessation, exercise and a healthy diet. In patients with diabetes, 
glycaemic control is also important. 
For the kidneys specifically, blood pressure and proteinuria control using angiotensin 
converting enzyme inhibitors or angiotensin II receptor antagonists are often helpful. 
Specific complications have to be treated with medication, such as anaemia with 
erythropoietin, and mineral and bone disorder with dietary changes as well as 
phosphate binders and calcitriol. Acid-base problems can be treated with bicarbonate 
or citrate. Specific dietary recommendations depend upon individual circumstances, 
and generally include reducing phosphate, potassium, and sodium intake (Rosenberg, 
2019). 
When symptoms cannot be controlled by lifestyle changes and medication alone, 
renal replacement therapy has to be considered. The most common form of renal 
replacement is haemodialysis, where blood is filtered using an artificial dialysis 
membrane outside the body. However, although dialysis techniques and technology 
have developed, there is still excess morbidity and mortality related to haemodialysis, 
with symptoms such as increased susceptibility to infection and subtle cognitive 
impairment, which are called the residual syndrome (Depner, 2001). Starting dialysis 
is a difficult decision, and the balance of benefits and risks has to be considered. This 
reminds us not only of the limits of dialysis, but also of our knowledge of uremic 
retention solutes and their mechanisms of toxicity. Peritoneal dialysis, where the 
peritoneum is used as the dialysis membrane, is an alternative; however, renal 
transplantation offers the best outcomes with regards to quality of life and mortality. 
 
1.1.4. ASSESSMENT OF KIDNEY FUNCTION 
The kidneys have multiple diverse functions, and how kidney function is measured 
today has a basis in how the understanding of kidney function has developed 
historically. As mentioned above, the early theories of urine formation were divided 
between filtration processes and tubular secretion, and glomerular filtration was first 
demonstrated decisively in 1924 (Jamison, 2014). Urea, which has the highest blood 
concentration of all uremic retention solutes, was first isolated in 1727 by Boerhaave, 
and improvements in urea measurement led to the discovery of urea retention in 
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animals after nephrectomy in 1823. Creatinine was discovered by Liebig in 1847, and 
although both urea and creatinine are freely filtered in the glomerulus, they are both 
affected by tubular secretion, and processes outside the kidneys (Duranton et al., 
2014, Narayanan and Appleton, 1980). Research in kidney disease has therefore been 
mainly based upon the filtration function of the kidneys and estimating filtration with 
urea and creatinine. However, given the important role of the kidneys in removing 
and processing other endogenous and exogenous compounds, there are many 
metabolites which are affected by CKD. Other aspects of kidney function are also 
becoming more important, as the limits of measuring filtration for diagnosis and of 
haemodialysis for treatment are becoming more apparent, and these will be discussed 
in the following subsections. 
 
1.1.4.1 Glomerular Filtration 
 
Figure 2. A nephron, the functional unit of the kidney, showing the glomerulus and Bowman’s 
capsule, where filtration occurs, and the renal tubule (PCT, loop of Henle, and DCT), where 
reabsorption and secretion take place. PCT, proximal convoluted tubule; DCT, distal 
convoluted tubule. Image licensed under Creative Commons BY 3.0 by Servier Medical Art 
(https://smart.servier.com/smart_image/nephron-3/).  
Measuring the filtration function of the kidney is the most widely used assessment of 
kidney disease in clinical practice. The glomerular filtration rate (GFR) is defined as 
the volume of fluid filtered through the glomeruli per unit time, and it can be 
calculated using the concentration of an ideal marker, and the following formula: 
 𝐺𝑙𝑜𝑚𝑒𝑟𝑢𝑙𝑎𝑟	𝐹𝑖𝑙𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑅𝑎𝑡𝑒 = 	01234	5637438198263	×	01234	;<6=	>984
?<9@A9	5637438198263
 
Equation 1. Glomerular filtration rate formula – based upon urine and plasma concentrations 










CHAPTER 1. INTRODUCTION 
19 
Measuring GFR is technically difficult, as an ideal marker of GFR should be freely 
filtered in the glomerulus, not secreted or reabsorbed by the tubules, and neither 
synthesised nor metabolised by the kidney. Markers such as inulin, iothalamate, 
iohexol, DTPA or EDTA are difficult to use, and therefore measuring GFR is most 
often substituted with an estimated GFR (eGFR) based on the endogenous metabolite 
creatinine. Creatinine is generated from the breakdown of creatine (mostly in 
muscle), and its concentrations depend upon multiple factors, such as muscle mass, 
diet, gender and race. Equations for estimating GFR from creatinine concentrations, 
to control for these factors have developed over time, the original Cockcroft-Gault 
formula dates back to 1973 and incorporates weight and age (Cockcroft and Gault, 
1976). Subsequent improvements include the Modification of Diet in Renal Disease 
(MDRD) study equation (Levey et al., 1999), and the CKD Epidemiology 
Collaboration (CKD-EPI) equation (Levey et al., 2009). 
Unfortunately, creatinine does not meet the assumptions required to be an ideal 
marker of GFR. Firstly, blood creatinine concentrations can be variable, for example, 
eating meat will increase serum concentrations transiently. Perhaps most importantly, 
early kidney disease will be compensated for by an increased tubular secretion, 
leading to artificially high estimates of GFR (Shemesh et al., 1985). The comparison 
of GFR and eGFR illustrated in Figure 3 clearly shows that precision decreases as 
eGFR increases, which leads to delays in diagnosis and limits early intervention. 
 
Figure 3. Comparison of the CKD-EPI and MDRD equations for estimating GFR. Although 
the CKD-EPI equation is more accurate overall, both equations are less precise as eGFR 
increases. The lines represent a smoothed regression line (solid) and 95% confidence interval 
(dashed). Reproduced with permission (Levey et al., 2009). Copyright (2009) The American 
College of Physicians. 
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1.1.4.2 Uremic Retention Solutes 
Urea and creatinine are the classical examples of metabolites which are not removed 
effectively from the circulation by failing kidneys, but long lists of compounds that 
are retained in CKD exist, and are continuingly being updated (Duranton et al., 2012). 
Criteria have been proposed to help find those that are toxic, such as Bergstom’s 
criteria (Bergstrom, 1997): 
1. Concentrations should be higher in uremic patients. 
2. Specific symptoms should be present, which are improved when 
concentrations are reduced. 
3. Symptoms should be reproducible in a control group exposed to increased 
concentrations. 
Unfortunately, no uremic retention solute has satisfied these criteria so far 
(Abramowitz et al., 2010). Urea concentrations rise more than any other solute in 
CKD, however, high concentrations of urea are well tolerated (Duranton et al., 2014). 
On the other hand, urea could potentially be toxic via protein modification, reactive 
oxygen species, ammonia production in the gut, or in combination with other uremic 
toxins (Abramowitz et al., 2010). Given the long list of uremic symptoms, and the 
multitude of possible interactions with other uremic solutes, finding metabolites that 
fulfil Bergstrom’s criteria can only get more difficult. 
The European Uremic Toxin (EUTox) group have published several reviews of 
uremic toxins, and have divided the solutes into three categories: free water-soluble 
low molecular mass compounds (<0.5 kDa), protein-bound solutes, and middle 
molecules (0.5-60 kDa) (Duranton et al., 2012). These categories are based upon 
molecular weight and protein binding, the significance being the links to how the 
compounds are processed by the kidney, and also to how they can be analysed. This 
also gives us some insight into the complexity of the transport systems present in the 
kidney, and that glomerular filtration is only one part of the process. 
 
1.1.4.3 Proteinuria – A Distinct Axis of Kidney Function 
Normal urine contains small amounts of a large variety of proteins. Larger plasma 
proteins are not filtered, because of the size and negative charge of the filtration 
barrier in the glomerulus, and the proteins that are filtered are normally efficiently 
reabsorbed. Proteinuria has been linked to disease for centuries (Diamantis et al., 
2008), and it is perhaps surprising that its role in CKD is still developing. Multiple 
studies have shown that higher levels of baseline proteinuria are linked to steeper 
declines in GFR, that proteinuria reduction slows progression of CKD, and the 
interaction of blood pressure and proteinuria, for example the landmark MDRD study 
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(Klahr et al., 1994, Peterson et al., 1995). More recently, a Kidney Disease: 
Improving Global Outcomes (KDIGO) group meta-analysis clearly showed the risks 
of high urine albumin-to-creatinine ratios (Levey et al., 2011). What was notable, 
however, was that this risk was independent of eGFR (Figure 4). 
 
Figure 4. Relative risks of various complications of CKD for different eGFRs, subdivided by 
the albumin-to-creatine ratio (ACR): blue, < 30 mg/g; green, 30-299 mg/g; red, ≥ 300 mg/g. 
The current threshold for CKD, defined by eGFR, is represented by the red arrow. Reproduced 
with permission (Levey et al., 2011). Copyright (2011) International Society of Nephrology. 
 
1.1.4.4 Diagnosis and Staging of CKD 
Currently, CKD is defined as an eGFR < 60 mL/min/1.73m2, or urinary albumin-to-
creatinine ratio (ACR) ≥ 30 mg/g, lasting for three or more months. Imaging of the 
kidneys is also useful, and in specific situations, tissue from a biopsy is needed for 
diagnosis (KDIGO 2012 Work Group, 2013). The staging (Figure 5) of CKD is based 
upon the risk of complications of different eGFR levels and ACRs (Levey et al., 
2011). Staging then guides treatment as well as monitoring. End stage renal disease 
is reached with an eGFR < 15 mL/min/1.73m2, and this indicates that renal 
replacement therapy with dialysis or transplantation may be necessary. 
The diagnosis of CKD is often made incidentally, for example when blood tests are 
taken for another reason, and in the early stages most patients have no symptoms. In 
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treat any risk factors. This naturally leads to the suggestion that screening may be 
useful, and this is discussed further in the following section. 
 
Figure 5. Staging of CKD using GFR and ACR according to the KDIGO 2012 Clinical 
Practice Guideline. Colours represent prognosis: green, low risk; yellow, moderately 
increased risk; orange, high risk; red, very high risk. Reproduced with permission (KDIGO 
2012 Work Group, 2013). Copyright (2013) International Society of Nephrology. 
 
1.1.4.5 Screening for CKD 
In Figure 5 above, the groups with an eGFR ≥ 60 ml/min/1.73m2 are especially 
interesting. Firstly, it is possible to slow GFR decline and delay end stage renal 
disease (Figure 1) with lifestyle changes and medication. Secondly, although the 
eGFR is in the “normal” range, there is still an increased risk when combined with 
other risk factors, in this case albuminuria. Therefore, screening could reduce the 
direct costs of renal replacement therapy over the long-term; reduce the indirect costs 
related to the increased risk of other diseases, especially cardiovascular disease; and 
improve quality of life parameters. Together with prevention, early detection and 
intervention are probably the most cost-effective methods of dealing with CKD, 
however, general screening for CKD has not been proven to be effective (Wouters et 
al., 2015). The widely accepted criteria for screening programs were developed by 











































G1 Normal or high ≥90
G2 Mildly decreased 60-89
G3a Mildly to moderately decreased 45-59
G3b Moderately to severely decreased 30-44
G4 Severely decreased 15-29
G5 Kidney failure <15
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Wilson and Jungner, and include balancing the costs of diagnosis and treatment, 
having a suitable test, and facilities for diagnosis and treatment (Wilson and Jungner, 
1968). Unfortunately, eGFR is not a suitable test, because it is not precise enough 
when eGFR ≥ 60 ml/min/1.73m2. 
Because population-based screening does not currently fulfil the criteria for 
screening, current research is based on screening high risk groups, for example 
individuals with hypertension, diabetes or a relevant family history (Brown et al., 
2003, Komenda et al., 2014). Other groups that are at a higher risk of CKD or faster 
progression of CKD, where screening may also be cost-effective, include African 
Americans and south Asians (Hoerger et al., 2012). In low- and middle-income 
countries where development is happening rapidly, such as India, the rates of diabetes 
and hypertension are also rapidly increasing. Although only a minority of these 
patients will reach end stage renal disease, targeted screening could improve the 
quality of life for many who cannot afford expensive healthcare, and cannot afford 
not to work (Varma, 2015). 
 
1.1.5. PROGRESSION OF CKD 
Even if the main cause of damage to the kidneys can be treated, kidney function often 
continues to deteriorate, and progression of CKD is thought to be inevitable. Bricker 
et al. proposed the “intact nephron hypothesis” in 1960, suggesting that a reduction 
in the number of functioning nephrons was an important part of chronic kidney 
disease (Bricker et al., 1960). They theorised that adaptation to reduced renal function 
leads to the remaining functioning nephrons having to increase their workload, and 
that this adaptation, although helping to maintain homeostasis in the short-term, can 
be maladaptive in the long-term (Bricker, 1972). 
One of the candidate maladaptive mechanisms is hyperfiltration, where there is an 
increase in intraglomerular pressure and glomerular hypertrophy to try to maintain 
GFR in individual nephrons, which eventually leads to secondary glomerulosclerosis 
(formation of scar tissue). In a similar way, high blood pressure may cause 
intraglomerular hypertension, where systemic hypertension is transmitted to the 
glomerulus, or via specific glomerular haemodynamic factors. Reducing proteinuria 
can delay progression, and the interaction between proteinuria and blood pressure is 
also important (Brenner et al., 1982, Klahr et al., 1994, Peterson et al., 1995). 
Acidosis occurs when the ability of the kidneys to excrete acid is overwhelmed. In 
the remaining functional nephrons, increased ammonium excretion is used to 
transport the excess acid, which leads to complement activation and is thought to be 
part of the mechanism that leads to further kidney damage (Nath et al., 1985, 
Simpson, 1971). Buffers are an important mitigating process, for example, 
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bicarbonate, phosphate and proteins. Bicarbonate concentrations are known to 
decrease as CKD progresses, and lower plasma bicarbonate concentrations are also 
linked to a greater risk of CKD progression in early disease (eGFR > 60 mL/min/1.73 
m2) (Driver et al., 2014).  
Healthy humans without CKD also lose about 4500 nephrons per year per kidney 
(Nyengaard and Bendtsen, 1992), and GFR falls by approximately 10 ml/min per 
decade (Davies and Shock, 1950). In common with many chronic diseases, changes 
associated with aging are observed at increased rates in the dialysis population, such 
as telomere loss, advanced glycation end products, oxidative stress and chronic 
inflammation (Kooman et al., 2013). It is therefore plausible to think of CKD as a 
form of accelerated aging in the kidney, and also to consider the number of nephrons 
at birth as a risk factor. 
 
1.1.6. PARTIAL NEPHRECTOMY ANIMAL MODELS OF CKD 
The 5/6 nephrectomy procedure has been used since the 1950s as a model for chronic 
kidney disease. It is based on the hypothesis that chronic renal disease can be 
represented as a decrease in the number of functional units of the kidney, leaving the 
rest of the nephrons to attempt to compensate for the functional loss (Platt et al., 
1952). There are many articles describing this model and the similarity it has to 
human CKD clinically, such as progressive GFR loss and proteinuria, as well as 
histopathological changes, including glomerulosclerosis and tubulointerstitial 
fibrosis (Kwon et al., 1998, Maddox et al., 1986, Morrison and Howard, 1966, 
Shimamura and Morrison, 1975). 
Various partial nephrectomy models are used experimentally, such as 
uninephrectomy, 2/3 nephrectomy and 5/6 nephrectomy, and there are also different 
methods of achieving renal mass reduction, for example, ligation of renal artery 
branches, or excision of the poles of the kidney. There are marked difference between 
these various models, and also between different strains and species. For example, 
GFR has been measured after 5/6 nephrectomy and uninephrectomy, and the 
maximal GFR increases were approximately 300% and 50%, respectively 
(Chamberlain and Shirley, 2007). Using infarction, as opposed to excision, to reduce 
renal mass seems to cause hypertension and more glomerular injury (Griffin et al., 
1994). An example of strain and gender effects is the male Sprague Dawley rat, which 
is particularly susceptible to ageing, with proteinuria in more than 50% at 12 months 
of age, over 90% by 24 months of age, and GFR decline after this (Goldstein et al., 
1988). 
Animal experiments allow us to conduct experiments in a highly controlled 
environment, thus helping to remove extra sources of variation. This is especially 
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important in ‘omics’ work, to reduce the risk of false positive findings when testing 
hundreds or thousands of variables. Animal models are also an important tool in 
testing possible interventions. However, the simplification has to be considered when 
discussing the relevance of findings to human disease. Human CKD is multifactorial, 
and although some animal models do involve multiple disease mechanisms, it will 
never be possible to capture all of the complexity. The genetics of inbred animal 
strains could also be markedly different to that of human disease, and the physiology 




CKD is an important global problem, the societal costs of CKD are still growing, and 
the future burden will disproportionately affect low- and middle-income countries. 
Prevention and early treatment could potentially save lives and costs, however early 
CKD is often missed, because early disease is asymptomatic and current methods 
based upon creatinine and eGFR are less precise in the early stages. 
Screening has not yet proven to be cost-effective, especially when based on 
population screening, but a test that could diagnose CKD at an earlier stage might 
change the balance of the argument. Early detection would make it possible to treat 
risk factors quickly, slow progression and prevent complications such as 
cardiovascular disease. Delaying end stage renal disease would not only improve 
quality of life, but would also reduce healthcare costs.  
Early detection, however, requires new biomarkers of kidney function that can be 
detected before serum creatinine rises and eGFR falls. Looking at other axes of 
kidney function, such as tubular secretion, could be helpful, and new markers of 
disease could eventually lead to a better understanding of the disease processes 
involved in triggering CKD, the progression of CKD, and the complications of CKD. 
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1.2. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) 
1.2.1. BACKGROUND 
Acute respiratory distress syndrome (ARDS) is a clinical syndrome which results in 
difficulty breathing after an insult to the lungs. There is no specific lung test or blood 
test, the insults causing it are varied, and only a minority of patients will get the illness 
after an insult. These issues make clinical suspicion of ARDS lower than it should 
be, which results in the syndrome being overlooked (Bellani et al., 2016). ARDS was 
first described in 1967 in a small group of critically ill patients, but it lacked an easy 
to use diagnostic scheme, which made studying and diagnosing the syndrome 
difficult (Ashbaugh et al., 1967). Diagnostic criteria were published in 1994, with 
four key components: an acute presentation; a low PaO2/FiO2 (ratio of partial pressure 
of oxygen in the blood to fraction of inspired oxygen); lung imaging changes; and 
the exclusion of heart failure or volume overload as a cause (Bernard et al., 1994). 
The criteria were updated in 2012 to improve clarity and reliability, although 
diagnostic issues still remain (ARDS Definition Task Force, 2012). 
The incidence of ARDS has been reported as approximately 80 per 100,000 person-
years by a study conducted in the USA, and the mortality rate here was estimated at 
40% (Rubenfeld et al., 2005). In a more recent study, over 10% of all ICU patients 
fulfilled the ARDS criteria, but clinical recognition was suboptimal (Bellani et al., 
2016). There are a large number of predisposing factors and, together with factors 
such as age and race, there is a large variation in the risk of ARDS and subsequent 
mortality (Rubenfeld et al., 2005). However, there seems to be a common 
inflammatory pathway which affects the smallest functional units of the lung, the 
alveoli (Figure 6). This disrupts both the endothelial (blood - alveolus) barrier and 
the epithelial (alveolus - air) barrier, as well as the interstitium in between, and this 
reduces gas exchange in the lung (Ware and Matthay, 2000). There is no treatment 
for ARDS itself, only supportive measures such as lung-protective mechanical 
ventilation and treatment of the underlying cause. 
Because of these diagnostic problems, there are some unresolved issues surrounding 
ARDS: is it possible to diagnose ARDS earlier or subclassify patients? Is it possible 
to treat ARDS more effectively, or event prevent ARDS? Can ARDS also occur 
outside of the intensive care unit? All of these issues require further research, and an 
effective diagnostic test. 
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Figure 6. Illustration of the airways in the lung. The alveoli are the smallest functional unit of 
the lung, where gas exchange between the blood and air occurs. Illustration: Colourbox.com. 
 
1.2.2. DIAGNOSING ARDS 
Diagnostic criteria for ARDS, known as the Berlin definition, have been developed, 
and require four conditions to be met: the condition has to occur within one week of 
a known clinical insult; blood oxygen levels must be low (Table 1); imaging must be 
consistent with ARDS; and cardiac failure or fluid overload must be (at least 
partially) excluded (ARDS Definition Task Force, 2012). The difficulties with these 
diagnostic criteria include: chest x-ray interpretation can be subjective, cardiac 
function may be difficult to assess, and the inhaled oxygen partial pressure (and the 
PaO2/FiO2 ratio) may be difficult to measure. Even lung biopsy is not a reliable 
diagnostic test in less severe disease (Cardinal-Fernández et al., 2016). In short, there 
is no definitive gold standard test for ARDS. 
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 PaO2/FiO2 (mmHg) PaO2/FiO2 (kPa) 
Mild 200 < PaO2/FiO2 ≤ 300 26.7 < PaO2/FiO2 ≤ 40 
Moderate 100 < PaO2/FiO2 ≤ 200 13.3 < PaO2/FiO2 ≤ 26.7 
Severe PaO2/FiO2 ≤ 100 PaO2/FiO2 ≤ 13.3 
Table 1. Oxygenation levels of mild, moderate and severe ARDS, defined according to the 
Berlin Criteria (ARDS Definition Task Force, 2012). The PaO2/FiO2 measure is the ratio of 
partial pressure of oxygen in the blood to the fraction of oxygen inspired. 
 
1.2.3. CAUSES AND RISK FACTORS OF ARDS 
ARDS can be triggered by direct or indirect insults to the lung. The direct insults, 
which are the most common, include pneumonia, aspiration of stomach contents, 
pulmonary contusion (trauma), fat emboli, inhalation of toxic gases, near-drowning 
and reperfusion injury. Indirect insults include sepsis, trauma (non-pulmonary), 
haemorrhagic shock, pancreatitis, major burns, drug overdose, blood transfusion, 
lung transplantation, and surgery involving cardiopulmonary bypass (Ware and 
Matthay, 2000). 
Cardiac surgery, such as coronary artery bypass graft (CABG) surgery, is normally 
performed by stopping the heart beating, and bypassing the heart and lungs with a 
mechanical pump and a membrane oxygenator, which is known as cardiopulmonary 
bypass (CPB). It has been hypothesised that the CPB circuit, or the surgical process 
involved in connecting the system to the patient, could be the cause of lung injury, 
but studies comparing traditional surgery with off-pump CABG have been mixed, 
and there is currently no consensus (Rong et al., 2016). 
Another risk factor is age, with a higher incidence and a higher mortality present in 
older patients (Rubenfeld et al., 2005). There are also recent papers that have found 
links between genes or gene expression and ARDS, including studies that have 
suggested neutrophil responses are one of the key differences in those who develop 
ARDS, compared to those who do not, following sepsis (Juss et al., 2015, Kangelaris 
et al., 2015). 
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1.2.4. MECHANISMS OF ARDS 
The blood-air interface in the lungs is a unique structure which has evolved to ensure 
efficient gas exchange. There are multiple mechanisms to keep the extremely small 
airspaces open and the distance between the airspace and the blood short. The 
alveolus, the smallest functional unit of the lungs, are lined by type I cells, which are 
thin and flat, and type II cells, which secrete surfactant to stop the alveoli from 
collapsing. The blood capillaries are lined by vascular endothelial cells, and between 
these surfaces is a thin interstitial space. The entire blood-air barrier is only a few 
micrometres thick, which is essential to allow oxygen and carbon dioxide to diffuse 
across efficiently (Matthay et al., 2019). 
In ARDS, the lining of the blood vessels becomes more permeable, and fluid and 
protein are pushed into the lung tissue and into the airspace of the alveoli. Fluid in 
the airspace and inflammatory processes in the tissue make it more difficult for gasses 
to diffuse across. This leads to respiratory failure, with low oxygen concentrations 
and high carbon dioxide concentrations in the blood. In addition to the cells lining 
the airspaces and blood vessels, immune cells are also important in the disease 
process, especially in the continuation or exacerbation of injury, and also in resolving 
the damage during the healing process (Matthay et al., 2019). 
There appear to be multiple phases in ARDS, for example an acute exudative phase 
which is followed by a proliferative phase, but histopathological changes show a 
great deal of heterogeneity. For example, there appears to be a hyperinflammatory 
subtype with different clinical features and different outcomes (Calfee et al., 2014). 
Apart from differences in the inflammatory response, many other mechanisms are 
also thought to play a role, such as mechanical damage from ventilation, ischaemia 
and reperfusion, and fluid balance. Connecting multiple, very different, risk factors 
to different pathological mechanisms is perhaps one of the reasons that ARDS 
mechanisms have been difficult to study, and treatment strategies hard to find. 
 
1.2.5. TREATMENT AND OUTCOMES OF ARDS 
Unfortunately, there is no effective pharmacotherapy for ARDS to date, and 
management consists of treating the cause or risk factors and supportive treatment. 
The role medical interventions play in causing or prolonging injury is the focus of 
much research, especially with regards to ventilation strategies. The lung-protective 
ventilation strategy uses a lower tidal volume than traditionally used, and has been 
shown to result in a lower mortality (Acute Respiratory Distress Syndrome Network, 
2000); and a conservative fluid management strategy has been shown to improve lung 
function, and shorten the duration of ventilation and intensive care treatment 
(National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome 
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(ARDS) Clinical Trials Network, 2006). Research studies have unsuccessfully 
trialled statins, corticosteroids and even aspirin in prevention, and although the results 
have all been negative, there have been interesting results involving subgroups of the 
data (Abdulnour et al., 2018, Matthay et al., 2019). 
As mentioned earlier, mortality following ARDS is extremely high, over 35 % in 
ventilated patients (Bellani et al., 2016). Pulmonary function, in those who survive, 
takes months to return to near normal levels, and there are multiple long-term 
problems, such as reduced quality of life and difficulty in returning to work 
(Davidson et al., 1999). These issues also suggest that treatment or prevention would 
be meaningful, and potentially cost-effective. 
 
1.2.6. SUMMARY 
ARDS can be a result of various diverse insults, which either directly or indirectly 
affect the lungs. There are various predisposing factors, different subtypes, different 
responses to treatment strategies, and heterogeneity in the time course, all making 
study of the disease difficult. As mentioned previously in connection to CKD, it is 
easier to study and treat an illness when it can be measured simply and objectively. 
Therefore, a diagnostic biomarker would be immensely useful, and in such a diverse 
syndrome, a biomarker that could subcategorise patients could help simplify research 
into the disease. 
 
  





Figure 7. A simplified diagram to illustrate some of the many ‘omics’ fields. 
Metabolomics is one of the newer ‘omics' fields, some of which are illustrated above, 
and it is complementary to genomics and proteomics (Fiehn, 2002). It involves the 
analysis of all (or as many as possible of) the small metabolites in a sample, from 
sugars and lipids, to amino acids and nucleotides. In plant metabolomics, the term 
primary metabolite is used to refer to those metabolites directly involved in normal 
growth, development and reproduction, and secondary metabolite to those not 
directly involved in these essential processes; whereas metabolites are normally 
divided into endogenous (made by the organism) or exogenous (not made by the 
organism itself) in human research. Metabonomics was a term defined as "the 
quantitative measurement of the dynamic multiparametric metabolic response of 
living systems to pathophysiological stimuli or genetic modification” by Nicholson 
et al. (1999); however, the terms metabonomics and metabolomics are often used 
interchangeably, and metabonomics could be considered a subset of metabolomics 
where the response to a stimulus or stressor is assessed. 
Metabolites are regulated by cellular processes, and can therefore be considered the 
end point of many cellular processes. However, one key difference to some other 
‘omics’ fields is the interaction of the environment and the host, which means that 
metabolite concentrations are not decided purely by the organism. Indeed, the 
importance of exogenous metabolites is becoming clearer with the analysis of the gut 
microbiota, where many metabolites have been found to be produced by bacteria 
living in the human gut (Zhang and Davies, 2016). Conversely, many drugs have 
been found to have an effect on, and possibly act via, the gut microbiome (Maier et 
al., 2018). 
The testing of individual metabolites goes back thousands of years, and medical 
professionals have combined results from multiple analyses or multiple sources of 
information to find a diagnosis for as long. The simultaneous analysis of multiple 
metabolites, providing a metabolic profile of an organism, was first demonstrated in 
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Horning et al. put forward the term "metabolic profile" in 1971 (Horning and 
Horning, 1971). Testing multiple metabolites simultaneously has evolved rapidly, not 
just in the field of metabolomics, but the large amounts of data produced have 
required new analysis methods and computing power, and the development of these 
started to take off in the 1970s and 1980s in the field known as chemometrics. 
Chemometrics developed in parallel with psychometrics and econometrics, as 
mathematical and statistical methods were used to analyse data in chemistry, 
psychology and economics (Wold, 1995). In the following sections I will briefly 
discuss both the methods used in chemical analysis to generate the data, and the 
methods used to analyse the large amounts of data. 
 
1.3.2. CHEMICAL ANALYSIS 
Chemical analysis, to quantify and identify metabolites, is a challenging process 
compared to other ‘omics’ fields, because metabolites have a wide variety of 
chemical composition, as well as a range of sizes, charges and concentrations. This 
means that no single chemical analysis method can cover the entire metabolome. 
Nuclear magnetic resonance spectroscopy (NMR) and mass spectrometry (MS) are 
the two most commonly used metabolomics platforms, and they have different 
metabolite coverages and sensitivities, and different strengths and weaknesses. Other 
methods include Raman spectroscopy and infrared spectroscopy, and all of these 
methods can be used in parallel to extract more chemical information. 
NMR is based upon the detection of NMR sensitive nuclei, and is described in detail 
below. Advantages of NMR over MS include better reproducibility, simpler sample 
preparation (which generally translates to faster analysis), the possibility of in-vivo 
studies using magnetic resonance spectroscopy (MRS), and the possibility of 
studying intact tissue samples using high-resolution magic-angle spinning (HRMAS) 
NMR spectroscopy (Bezabeh et al., 2014, Markley et al., 2017). Simpler sample 
preparation is also important in minimising variability at this experimental stage, 
which helps to reduce false positive or false negative results. NMR spectra can also 
be used directly to deduce metabolite structure and identity, even of unknown or new 
compounds. 
MS is normally used in combination with a chromatography step, for example gas or 
liquid chromatography (GC or LC), which separates the metabolites via differing 
physicochemical properties, such as polarity or volatility. MS involves the detection 
of ions, so metabolites must first be ionised, and different processes can be used to 
achieve ionisation, although not all metabolites can be ionised equally well. Once 
metabolites are ionised, a detector can then register their mass-to-charge ratio. 
Coupling different chromatography steps with different ionisation methods, and 
using different MS detection methods, means that there is a large variety of different 
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combinations which can be used in parallel to gain better coverage of the 
metabolome. 
Advantages of MS over NMR, dependent upon which chromatography method is 
used, include the higher sensitivity and higher specificity possible, which means that 
smaller sample volumes are needed and more metabolites can be detected. Targeted 
analysis is also possible, again depending upon the type of equipment used, and start-
up costs are also potentially much smaller. Because of these advantages, the number 
of MS-based publications is growing faster than NMR-based publications, however, 
as discussed earlier, NMR still offers advantages that are important and relevant.  
The identification of metabolites found in the spectra normally requires a database of 
metabolites, for example, METLIN or HMDB (Guijas et al., 2018, Wishart et al., 
2018). The number of known metabolites is constantly increasing, for example, the 
Human Metabolome Database (HMDB) contained about 2180 human metabolites in 
version 1 (2007), 6408 in version 2 (2009), 40153 in version 3 (2013), and 114100 
in version 4 (2018) (Wishart et al., 2018). METLIN contains over one million 
compounds (Guijas et al., 2018). These huge numbers illustrate how complex 
metabolomics is becoming, especially metabolite identification and pathway 
analysis. 
 
1.3.2.1 Fundamentals of NMR Spectroscopy 
The theoretical basis of NMR spectroscopy can be described using either classical 
mechanics or quantum mechanics. Although classical mechanics has limitations, it is 
easier to conceptualise, and therefore the following explanation of the principles of 
NMR spectroscopy will be based on classical mechanics. 
Spin is a property of elementary particles and is a form of angular momentum. Nuclei 
with an odd number of protons and/or neutrons have a non-zero nuclear spin and 
possess the properties of a magnetic dipole, known as the nuclear magnetic moment. 
The most common nuclei used for NMR are 1H, 13C, 15N and 31P, which all have a 
spin quantum number of ½. With a spin quantum number of ½, the simplest case for 
NMR-sensitive nuclei, when the nuclei are placed in a constant magnetic field (B0) 
they will have two possible states, either parallel (spin-up), or anti-parallel (spin-
down), to the magnetic field. There is a difference in energy between these two states, 
given by Equation 2. 
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∆𝐸 = 𝛾ℎ𝐵G/2𝜋 
Equation 2. The difference in energy between the two states (ΔE) is proportional to the 
gyromagnetic ratio of the nucleus (𝛾) and the magnetic field strength (B0). h represents 
Planck’s constant.  
Slightly more spins are in the low energy state (parallel to the magnetic field), with 
the probabilities given by the Boltzmann distribution (Equation 3). This population 
difference, between parallel and anti-parallel spins, results in a net spin magnetisation 
along the B0 direction. However, this population difference is exceedingly small, 
which is part of the reason that NMR is relatively insensitive, although sensitivity 








Equation 3. The probability (p) of a nucleus being in the high energy anti-parallel state is 
related to the gyromagnetic ratio (𝛾), the magnetic field strength (B0), and the temperature 
(T). h represents Planck’s constant and k represents the Boltzmann constant. 
The spins, however, are not simply pointing up and down in the magnetic field, but 
also precessing around this axis. This precession has an associated frequency, known 
as the Larmor frequency (Equation 4). When an oscillating magnetic field is applied 
at this frequency, the net magnetisation will be rotated. If this pulse is carefully 
calibrated, the magnetisation will be flipped by 90°, and as this magnetic moment 
precesses and decays, it produces a radiofrequency signal that can be measured. 
Although all 1H nuclei (protons) have the same gyromagnetic ratio, they do not 
experience the same magnetic field. This is due to shielding of the nuclei by the 
electrons, which depends upon the chemical structure of the molecule, and means 
that nuclei in different molecules will produce signals of different frequencies. 
Decoding the frequencies from the NMR signal, which contains information from all 
the protons in the sample, requires Fourier transformation. The resonant frequency is 
normally reported relative to a reference compound, as chemical shift in parts per 
million (ppm). 
𝜔 = 𝛾𝐵G  
Equation 4. The precession frequency is determined by the gyromagnetic ratio (𝛾) and the 
magnetic field strength (B0). 
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1.3.2.2 Extracting Information From NMR Spectra 
Chemical shift contains information about chemical structure, because chemical 
groups have typical chemical shift ranges. Other information that is available directly 
from the NMR spectrum is the relative concentration of different protons. For 
example, an NMR spectrum of ethanol, a simple molecule consisting of a CH3 group, 
a CH2 group and an OH group, would have the CH3 and CH2 protons located in 
different regions, and they would have a peak area ratio of 3:2 (Figure 8). The OH 
proton signal is normally lost due to exchange with the solvent protons (H2O and 
D2O). 
 
Figure 8. Proton NMR spectrum of ethanol. The CH3 group protons are located at 
approximately 1.2 ppm, whilst the CH2 group protons are located at approximately 3.6 ppm. 
Relaxation results in decay of the NMR signal. It occurs in two different ways, either 
spin-lattice (T1) relaxation, or spin-spin (T2) relaxation. Spin-lattice (T1) relaxation 
causes loss of signal intensity, and the return of the equilibrium net magnetisation 
along the B0 axis. Although spin-spin (T2) relaxation also causes signal loss, this is 
due to loss of coherence in the xy plane (perpendicular to B0) because of interactions 
with other magnetic dipoles. These processes can be used to provide extra 
information about the physicochemical surroundings of the proton, and they can also 
be used to filter the signal. For example, T2 filtering can be used to reduce the signals 
from large molecules such as proteins, which tend to have shorter T2 times. 
Scalar coupling (also known as J-coupling) is due to the interaction of spins through 
chemical bonds, and results in the splitting of NMR signals. For example, in the 
ethanol spectrum (Figure 8), the signal from the CH3 protons will be split by the CH2 
protons into a triplet (with intensity ratio 1:2:1), and the CH2 peak will be split into a 
quartet (with intensity ratio 1:3:3:1) by the CH3 protons. 
Two-dimensional NMR spectroscopy is used to deduce information about which 
nuclei are close to each other. This can be achieved through coupling, using 
correlation spectroscopy (COSY) or total correlation spectroscopy (TOCSY), and 
even through space using nuclear Overhauser effect spectroscopy (NOESY). It is also 
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13C, using heteronuclear correlation experiments such as heteronuclear single-
quantum correlation spectroscopy (HSQC) or heteronuclear multiple-bond 
correlation spectroscopy (HMBC). Two-dimensional spectra can also be generated 
by using other types of information along the second axis. The J-coupling information 
mentioned earlier can be moved onto the y-axis to construct simpler spectra, with less 
peak overlap along the x-axis. Diffusion coefficients can also be measured with NMR 
experiments, and plotted on the y-axis, resulting in diffusion ordered spectroscopy 
(DOSY). 
By combining information from two or more of these different experiments, peaks in 
the NMR spectra can be identified, and by integrating NMR peaks, metabolites can 
be quantified. However, care has to be taken to ensure that certain assumptions have 
been met, and if these assumptions cannot be met, relative quantitation can be used 
instead of absolute quantitation.  
 
1.3.2.3 NMR Pulse Sequences 
Although a simple 90° pulse would result in an NMR signal, called a free induction 
decay (Figure 9A), most modern pulse sequences are a combination of multiple 
pulses. These pulse sequences are designed to: alleviate experimental problems, such 
as magnetic field inhomogeneity or the large concentration of protons in water; 
simplify complex and crowded spectra; or obtain extra information about the 
metabolites (as discussed above). The simplest addition is called presaturation, where 
irradiation at the specific frequency of an unwanted signal, such as the solvent signal, 
at a low power for a relatively long duration will cause the solvent signals to become 
saturated. This results in a minimisation of the difference in the number of nuclei in 
the high and low energy states, and the resulting NMR signal. Presaturation is 
normally applied during the delay between repetitions of the pulse sequence. 
In the 1D NOESY experiment (Figure 9B), the single 90° pulse is replaced by three 
90° pulses. Together with phase cycling, this has the effect of reducing problems 
caused by the edges of the sample, which are in a less homogenous region of the 
magnetic field. A typical serum NOESY spectrum is illustrated in Figure 10A. In the 
Carr-Purcell-Meiboom-Gill (CPMG) experiment (Figure 9C), a repeated 180° pulse 
with associated delays is added to the 90° pulse. This addition has the ability to 
attenuate signals based upon their T2 relaxation times, and because large molecules 
such as proteins have shorter T2 times, their signals will be lost more quickly than 
small metabolites. This method is known as T2 filtering, and results in an improved 
baseline in protein-rich samples (Figure 10B). This filtering, however, can also 
attenuate signals from metabolites with longer T2 times and therefore alters the 
quantitative nature of the NMR spectra. 
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Figure 9. (A) Basic 90° NMR pulse followed by signal acquisition of the free induction decay 
(FID). (B) 1D NOESY NMR pulse sequence with two extra 90° pulses. (C) CPMG NMR pulse 
sequence, where the bracketed 180° pulse is repeated n times. (D) J-resolved NMR pulse 
sequence, recorded with varying delays (𝜏) to enable J-coupling to be analysed in a two-
dimensional spectrum. 
The J-resolved experiment (Figure 9D) is a two-dimensional NMR experiment, 
where the J-coupling (mentioned earlier) is moved into the second dimension. This 
is achieved by a spin echo pulse sequence (90° pulse followed by a 180° pulse) with 
varying delays (𝜏). During these delays, the J-coupling continues to evolve, whilst 
the chemical shift evolution is refocused. This type of spectrum is often “projected” 
into one dimension, so that multivariate analysis can be performed on a simplified 
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Figure 10. Example NMR spectra of a single serum sample: (A) NOESY, with contributions 
from small metabolites and large proteins; (B) CPMG, which has a much flatter baseline due 
to filtering of the macromolecule signals; and (C) pJRES, where the J-coupling is removed, 
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1.3.3. MULTIVARIATE ANALYSIS (CHEMOMETRICS) 
Chemical analysis results in a table of data, ideally a list of concentrations of different 
metabolites in different samples. However, the table is often a list of the response of 
the chemical detector at different positions on a separation scale, for example 
frequency in parts per million (ppm) for NMR or mass-to-charge ratio for MS. Often 
there is more than one separation scale, such as the chromatography axis, and often 
there are multiple samples per individual. This results in a messy data structure, 
where much of it contains no information (noise), and some regions contain 
overlapping metabolite signals. Differences between individuals which are unrelated 
to the specific study are an additional layer of complexity, and there may also be 
missing data. To find the relevant patterns in these complex datasets, it is necessary 
to turn to algorithms and computer processing power. 
Algorithms used in metabolomics include principal component analysis (PCA), 
partial least squares regression (PLS), and partial least squares discriminant analysis 
(PLS-DA), which were used in this thesis. Other algorithms include factor analysis, 
K-means clustering, artificial neural networks, support vector machines, and 
Bayesian networks. Some of these methods are based upon statistical methods, whilst 
others are based upon geometric methods, although there is overlap, and the term data 
science is possibly flexible enough to cover the various and widely differing 
approaches.  
 
1.3.3.1 Principal Component Analysis and Partial Least Squares 
Regression 
PCA was developed at the beginning of the 20th century by Karl Pearson (1901). It 
is an orthogonal linear transformation, which expresses the data (the X matrix) in a 
new coordinate system in order to maximise the variance on the first axis. The 
subsequent axes are found by removing the contribution of the first axis, and finding 
the next orthogonal axis with the next largest variance. By finding the maximum 
variance in the data, it is hoped that interesting or relevant patterns can be found. The 
first few principal components (the new coordinate system) offer a simplified view 
of the data, and PCA is often used to reduce the dimensionality of large data sets, 
although there is no guarantee that the first components will contain the grouping that 
is of interest to the study. The data can be visualised in the new coordinate system, 
which is called a scores plot, whilst the contribution of the original variables to the 
new coordinates system is known as a loadings plot (illustrated in Figure 11). 
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Figure 11. Using PCA on a dataset to produce scores and loadings plots. Three variables (x1, 
x2 and x3) can be transformed onto two principal components (t1 and t2), which reveals a 
difference between the two groups. Reproduced with permission (Trygg et al., 2007). 
Copyright (2007) American Chemical Society. 
Whereas PCA is an unsupervised method, PLS is a supervised method where extra 
information (the Y matrix), such as treatment group or outcome, is used to find the 
relationship between the two sets of data. In a similar way to PCA, new axes are 
found, but these axes try to capture the variance in both the data (the X matrix) and 
the extra information (the Y matrix). PLS-DA is simply PLS where the Y matrix 
consists of categorical information. 
 
1.3.3.2 Pre-processing 
As alluded to above, PCA and PLS do not always find new axes that are relevant to 
the study. This can be due to patterns and groupings that are significant, but not 
immediately interesting, but this can also be due to variation in the data that is 
irrelevant. The most obvious source of unwanted differences is in sample 
concentration. This can be dealt with by normalising the data, ideally with 
information about the original sample size or concentration. If this is unknown, other 
normalisation procedures can be tried, for example by using: signals in the sample 
which are thought to be constant; the total intensity of all signals; an internal standard, 
added after sample collection; and if the analytical system is stable enough, an 
external standard. If none of these methods are suitable, different algorithms can be 
used to make the samples more comparable (Emwas et al., 2018). 
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Another source of unwanted variation relates to the magnitude of individual 
variables, because the relative size of the variables affects the magnitude of the 
variance, and therefore, variables of larger intensity will generally dominate the 
model. This can be useful, as noise is normally present at a much smaller magnitude 
than signal, but it can also be a problem when unimportant signals are larger than 
important signals. This problem can be mitigated by scaling the data, where variables 
are divided by a scaling factor such as the standard deviation, or the square root of 
the standard deviation, of the particular variable. Other pre-processing steps that are 
used include mean centring, used to remove the average from the data, and log 
transformation, which can be helpful in reducing heteroscedasticity (van den Berg et 
al., 2006).  
Data can also suffer from alignment problems, also known as the correspondence 
problem, where peaks corresponding to the same metabolite do not appear in the same 
position (Aberg et al., 2009). In NMR, this can be due to small differences in sample 
pH, temperature, or metal ion concentration, and some alignment problems can be 
improved with algorithms such as icoshift (Savorani et al., 2010). However, whilst 
this can cause difficulties in data analysis, it can also be an extra source of 
information, especially in urine NMR-based metabolomics, where recent studies 
have highlighted the possibility of predicting the concentration of NMR invisible ions 
from the chemical shift of NMR visible metabolites (Takis et al., 2017, Tredwell et 
al., 2016). 
 
1.3.3.3 Outliers, Overfitting and Validation 
During model building, the complexity of the model has to be determined, and 
whether or not outlying samples should be excluded from the process. The most 
serious problem, however, is over-fitting the data, i.e. making the model so complex 
that it only fits the data that has been used to train it. In a similar way, outlying 
samples can dominate the model, and therefore make it less generalisable. Validation 
is a term for a number of techniques which can be used to decide on the appropriate 
level of model complexity, to decide which outlying samples need to be removed, 
and to assess the model performance. One of the simplest methods is cross-validation, 
which is accomplished by leaving a small number of samples out, building the model 
on the remaining data, and then testing how well the model predicts the samples that 
have been left out. This can be repeated to use different samples, and arrive at a 
cumulative result for the whole dataset. 
Other methods to assess the model include permutation testing, jackknifing or 
bootstrapping. Unfortunately, even after these validation steps, models can be over 
optimistic, or important variables can be missed. Testing the model on an 
independent dataset, a completely new block of data which has not been used to build 
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and optimise the model, is extremely important and is the best way to critically assess 
a model and to avoid bias. These problems are discussed further below in section 
1.3.6. 
 
1.3.4. ‘OMICS’ STUDIES IN CKD 
‘Omics’ studies have many possible roles in medicine. For example, they can be used 
to better subclassify disease, or even reclassify diseases, which can result in more 
effective and personalised treatments. New biomarkers can also be useful for 
diagnosing disease, monitoring disease and monitoring treatment, whilst new 
findings can lead to a better understanding of the mechanisms of disease. 
Genomics has been successfully used to find some of the genetic causes of kidney 
diseases, such as autosomal dominant polycystic kidney disease and Alport 
syndrome. Although relatively common monogenic disorders are the easiest to 
investigate, there have also been some findings linking genes to the risk of kidney 
disease, and others estimating the heritability of GFR (Nadkarni and Horowitz, 
2016). One example is the APOL1 gene risk alleles, which have been found to lead 
to a greater risk of focal segmental glomerulosclerosis or hypertensive end-stage 
kidney disease, and which are common amongst African Americans (Friedman and 
Pollak, 2011). 
Proteomics has been used extensively in CKD, and has, for example, led to the 
discovery and validation of CKD273, a panel of 273 urinary peptides which was 
better at detecting and predicting progression of CKD than albuminuria and baseline 
eGFR (Schanstra et al., 2015). Other protein markers (not necessarily discovered by 
proteomics studies) such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-
associated lipocalin (NGAL), N-acetyl-ß-D-glucosaminidase (NAG) and liver fatty 
acid binding protein (L-FABP) have been assessed, and do not seem to improve on 
the predictive values of eGFR and ACR (Hsu et al., 2017). Cystatin C, a protein 
produced by all nucleated cells, which is freely filtered in the glomerulus and then 
reabsorbed and catabolised in the kidney, is the only new biomarker that is close to 
clinical use. It has been used to estimate GFR, and when used in combination with 
creatinine, has proven to be more accurate and more precise than either marker alone 
(Inker et al., 2012). Studies have also shown that cystatin C levels are a better 
predictor of morbidity and mortality in the elderly than eGFR (Shlipak et al., 2005). 
Much research has been published using metabolomics methods in kidney disease. 
Most early studies looked at acute kidney injury (AKI) after an insult to the kidneys, 
often in animal models, but metabolomics articles about CKD in humans are 
increasing in number. One of the first uses of GC-MS in CKD was an analysis of 
serum (Niwa et al., 1979), whilst one of the first NMR papers was published later 
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(Bell et al., 1991). Examples of metabolites that have been confirmed to be altered in 
CKD by metabolomics studies include amino acid derivatives, such as the tryptophan 
metabolites indoxyl sulfate and p-cresyl sulfate; the arginine metabolites, symmetric 
and asymmetric dimethylarginine (SDMA and ADMA); and phenylacetylglycine, a 
glycine conjugate of phenylacetic acid (Zhao, 2013). Purine metabolites such as 
hypoxanthine, xanthine, uric acid and allantoin have also been found to be 
significantly different in animal models of CKD (Zhao et al., 2011, Zhao et al., 2013). 
And a comparison of haemodialysis patients, peritoneal dialysis patients and controls 
revealed that hypoxanthine and inosine were only detected in the haemodialysis 
group (Choi et al., 2011). Plasma concentrations of carnitine and acylcarnitines have 
been found to be inversely correlated with eGFR in a large population study (Goek 
et al., 2012), but carnitine was found to positively correlate with eGFR in another 
study (Yu et al., 2014). Many fatty acids have also been described to be affected by 
CKD in metabolomics studies (Rhee et al., 2010, Zhao et al., 2013). 
The difficulty using metabolomics in CKD is trying to distinguish between 
metabolites that accumulate because of reduced kidney function and those that are 
toxic and actually cause morbidity and mortality. It is relatively easy to apply new 
metabolomics techniques to find new metabolites affected by CKD, but it is more 
difficult to connect these metabolites to disease processes or outcome. However, 
there has been some recent progress in large-scale studies looking at biomarkers that 
can predict incident CKD, or that are linked to future morbidity or mortality. For 
example, Rhee et al. applied LC-MS-based metabolomics to 1434 participants from 
the Framingham Heart Study who did not have CKD, and found 16 metabolites to be 
significantly different in those who went on to develop CKD during follow up (Rhee 
et al., 2013). Goek et al. followed 1104 participants in the Cooperative Health 
Research in the Region of Augsburg (KORA) cohort and found a significant 
association between the annual change in eGFR and baseline levels of three 
metabolites or metabolite ratios; and they also found a link between the kynurenine-
to-tryptophan ratio and a subsequent new diagnosis of CKD (Goek et al., 2013). Yu 
et al. used GC-MS and LC-MS metabolomics on serum from 1921 participants in the 
Atherosclerosis Risk in Communities (ARIC) study and found that baseline 5-
oxoproline and 1,5-anhydroglucitol levels were significantly associated with new 
cases of CKD. But the predictions based upon these metabolites did not improve on 
clinical models based upon traditional risk factors, such as blood pressure, diabetes, 
cholesterol and smoking (Yu et al., 2014). 
In the only large-scale study to be validated in a completely independent test set, Hu 
et al. investigated the relationship between serum metabolites and all-cause mortality 
(up to 19 years later) in 299 patients from the Modification of Diet in Renal Disease 
(MDRD) cohort, and then validated their findings using data from 963 patients in the 
African American Study of Kidney Disease and Hypertension (AASK) cohort. Three 
metabolites were significant in both cohorts: ribonate, fumarate and allantoin (Hu et 
al., 2018). 
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In summary, there have been many interesting findings, and metabolomics has found 
many metabolites that have altered concentrations in CKD. However, a consensus is 
lacking, connecting findings to disease mechanisms is problematic, and focusing on 
eGFR ignores losses of other important kidney functions. Furthermore, large-scale 
and adequately validated research is only appearing slowly. 
 
1.3.5. ‘OMICS’ STUDIES IN ARDS 
There is not as much literature on ARDS compared to CKD, presumably because 
ARDS has not existed for as long as CKD, but also because it is more heterogenous, 
and therefore more difficult to study. The role of the kidneys in removing substances 
from the blood also makes it easier to find metabolites that are significantly affected 
in CKD. Most ‘omics’ studies on lung diseases are based on the chronic diseases 
asthma and COPD, and currently most research in ARDS has been conducted on 
protein markers. For example, serum lipopolysaccharide binding protein (LBP) 
concentrations were found to be higher in septic patients who subsequently developed 
ARDS (Villar et al., 2009). Another protein, the soluble receptor for advanced 
glycation end-products (sRAGE), is highly expressed in the lung epithelium. Studies 
have shown that blood levels of sRAGE are associated with the severity of lung injury 
or mortality (Calfee et al., 2008, Uchida et al., 2006), and plasma levels of sRAGE 
have been linked to respiratory failure after cardiac surgery (Uchida et al., 2013). 
Interleukin-8 (IL-8), which is a pro-inflammatory cytokine, has also been associated 
with mortality and the risk of developing ARDS (Donnelly et al., 1993, Parsons et 
al., 2005). Other proteins that have been studied include angiopoietin-2, surfactant 
protein D and procollagen peptides. None of these markers are in routine clinical use 
and, because of the limited individual predictive value of these biomarkers, research 
has been carried out on combinations of them. For example, a panel of seven 
biomarkers including RAGE, procollagen peptide III, brain natriuretic peptide, 
angiopoietin-2, tumour necrosis factor alpha, IL-8 and IL-10 produced a predictive 
model with an area under the receiver operating characteristic (AUROC) curve of 
0.86 (Fremont et al., 2010). 
Plasma free fatty acids have been studied by Shi et al., and higher concentrations 
were associated with lower PaO2/FiO2 ratios postoperatively (Shi et al., 2015). 
Stringer et al. compared plasma from patients with sepsis-induced ARDS and healthy 
controls, and found significant differences in glutathione, adenosine, 
phosphatidylserine and sphingomyelin concentrations (Stringer et al., 2011). Evans 
et al. analysed bronchoalveolar lavage fluid (BALF) from ARDS patients and healthy 
controls, and found much higher concentrations of many metabolites, including: 
hypoxanthine, guanosine, uridine, xanthine, hippurate, leucine, proline, glutamate, 
phenylalanine, threonate, tyrosine, tryptophan, creatinine, creatine, acetylcarnitine, 
citrate, lactate, cis-aconitate, and 2-oxoglutarate; whereas it was mostly fatty acids 
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that were at much lower levels in ARDS patients, including many 
phosphatidylcholines (Evans et al., 2014). Testing exhaled breath for volatile organic 
compounds (VOCs) is a promising method to non-invasively assess the lungs. In one 
paper three VOCs, octane, acetaldehyde and 3-methylheptane, were found to be 
significantly higher in ARDS patients using GC-MS (Bos et al., 2014), and in another 
paper isoprene was significantly lower in exhaled breath from ARDS patients 
(Schubert et al., 1998).  
Genomics studies are difficult to conduct in such a varied and rare disease, but the 
first genome-wide association study in ARDS identified 159 significantly associated 
single-nucleotide polymorphisms (SNPs) (Christie et al., 2012), whilst a more recent 
paper identified SNPs within the selectin P ligand gene (Bime et al., 2018). 
Transcriptomics studies have also been conducted, reporting, for example, significant 
changes in neutrophil-related pathways in early disease (Kangelaris et al., 2015). As 
with all the other ‘omics’ technologies, robust validation and lack of consensus of 
findings is still a problem. 
Perhaps the most interesting studies have been those that are able to stratify patients. 
For example, Bos et al. have described a distinct “reactive phenotype” in patients 
with sepsis and ARDS, where one third of genes were expressed differently in a 
transcriptomics study carried out on white blood cells (Bos et al., 2019). Rogers et al. 
compared lung oedema fluid from patients with ARDS and patients with hydrostatic 
oedema, and found a subset of ARDS patients with very high levels of many 
metabolites; this subset also had a much higher mortality (Rogers et al., 2017). 
Although not an ‘omics’ study, Calfee et al. also found distinct phenotypes, based 
upon clinical and biochemical characteristics, with significant differences in 
mortality, ventilator-free days and organ failure-free days (Calfee et al., 2014). 
Although ‘omics’ studies can potentially offer much to ARDS and other diseases 
where the pathological mechanisms are still being resolved, there are plenty of 
problems where there is currently no gold standard diagnostic test. Perhaps the best 
studies have been those that attempt to subcategorise patients, which suggests that 
targeting treatment may be useful and that further research should probably focus on 
individual subcategories. 
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1.3.6. ISSUES SURROUNDING ‘OMICS’ STUDIES 
Many of the limitations of metabolomics are shared with the other ‘omics’ fields 
because of the statistical problems caused by a large number of variables and a 
relatively small number of samples. Metabolomics has some advantages over 
proteomics and genomics, for example, because metabolites are the end products of 
gene and protein regulation they can represent variation as a result of gene and protein 
differences as well as a result of responses to environmental factors. Another 
advantage is that there are a smaller number of metabolites than genes or proteins, 
which makes data analysis easier, although this is more than overwhelmed by the 
complexity of the multiple chemistries involved (Weiss and Kim, 2011). Some 




Many papers have reported on the reproducibility problems in science (Begley and 
Ioannidis, 2015). All of the ‘omics’ fields suffer from these problems because of the 
huge amount of data generated. Firstly, the data is noisy, either due to experimental 
issues or because of variation in the subject group, which can lead to misleading 
results. Secondly, in what has been described as the “fishing expedition” problem 
(Ning and Lo, 2010), many articles are small-scale discovery-mode studies based 
upon this unavoidably noisy data, and large-scale validation studies are rare. 
Reproducibility is also a problem due to the use of univariate statistical methods after 
multivariate analysis. With such a large number of variables and a relatively small 
number of samples, all ‘omics’ experiments suffer from the “curse of dimensionality” 
(Altman and Krzywinski, 2018). This “large p small n” problem causes problems for 
traditional statistical methods, and can lead to type 1 errors (false positives, or finding 
something significant by chance alone), and type 2 errors (false negatives, or 
rejecting something that is actually significant), because sample sizes are small, and 
therefore the power of the study is small. Also, the requirement to keep the data used 
for validation separate from the data used to build the model also holds for the data 
used for statistical testing. In other words, using the same data to generate hypotheses 
and statistically test these hypotheses will result in more type 1 errors (false 
positives). This has been described as “post-hoc theorising”. Testing potentially 
useful biomarkers with satisfactory validation studies in a sufficiently large and 
independent group is necessary to avoid these problems.  
Other problems with validation arise because models based upon one group cannot 
necessarily be used on another group, for example, models based on patients from 
one part of the world or one gender may not be applicable to patients from another 
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part of the world or another gender. Confirmation of results may also be difficult if 
different analytical techniques are used, which do not necessarily cover the same 
metabolites. These issues are a particular problem in heterogenous diseases, such as 
ARDS, where there are a variety of initial insults, for example, some studies are based 
upon ARDS following sepsis whilst others are based upon ARDS following trauma. 
Another problem with ARDS is the lack of a gold standard diagnostic test, with 
differences in diagnosis potentially adding to the complexity of validation studies. 
These problems are clearly seen in the ‘omics’ in CKD and ARDS sections above 
(sections 1.3.4 and 1.3.5), where there is a lack of consensus about which metabolites, 
proteins and genes are significant across the various studies. Sometimes the problems 
occur because the different groups are not comparable, or because of different 
analytical methods; but incorrect metabolite identification of metabolites, and false 
positive findings are also potential reasons (Scalbert et al., 2009). We must also 
remember that this variability, and the amount of detail that ‘omics’ technologies 
provide, is a source of information. For example, there are many potential sources of 
variability that have not been analysed in these studies, such as diet, exercise, and 
diurnal rhythm. Also, as mentioned previously, diseases can have very different 
manifestations at different stages, and can be, or have been historically, subdivided 
in many different ways. And although we may not currently have the ability to deal 
with this complexity now, computational and mathematical methods are developing 
and will be able to solve these problems in the future. Other ways of handling this 
complexity include: carefully designed temporal, or crossover studies, where subjects 
are their own controls; animal experiments, where some sources of variability can be 
controlled; and meta-analysis of data sets to find common metabolites affected across 
multiple studies (Scalbert et al., 2009). 
 
1.3.6.2 Correlation, Causality and Surrogate Markers 
Metabolomics and multivariate analysis, in their simplest forms, can only find 
correlations between two variables and cannot find a causal link between the 
variables. This is reasonable for ‘omics’ studies, which are generally hypothesis 
generating, but proving causality is also important. The subject of causality, however, 
is more complex than it seems. The “causal pie model” was developed by Rothman 
(1976) and tries to explain the complexity of multifactorial situations, where more 
than one combination of factors can cause a particular disease (Figure 12). There may 
be one common factor in all of these combinations (a component necessary cause), 
or one factor may only be present in one combination (a component cause), or one 
factor on its own may be enough to cause the illness (a sufficient cause). Investigating 
complex multifactorial disease is difficult, and Ghezzi et al. have suggested that 
"conventional statistical analysis and study design will favour the identification of a 
causally irrelevant prognostic biomarker” (Ghezzi et al., 2018). 
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Figure 12. Representation of different relationships between causes and disease. Oxidative 
stress (OS, red slices), for example, can be: a component necessary cause (A); a component, 
but not necessary, cause (B); or a sufficient cause (C). Reproduced with permission (Ghezzi et 
al., 2018). Copyright (2018) National Academy of Sciences. 
This ties into the reproducibility problems mentioned earlier, as a factor that causes 
illness in one group may not be important in another group, and therefore may not be 
able to be validated using traditional statistical methods on the entire group. And 
‘omics’ studies on real patients with multifactorial diseases may tend to pick up the 
common downstream events, which are not directly related to the disease. 
Surrogate markers are another complicating issue in CKD and ARDS. CKD is a 
disease that develops slowly and the initial phase, which is often asymptomatic, can 
last for many years (Stevens et al., 2006). Even after symptoms occur, it can take 
many years before hard endpoints are reached, for example death or ESRD. This 
makes it difficult to conduct research on biomarkers and treatments, as patient follow 
up over years or decades would be necessary, and even then, many patients die of 
other causes before reaching ESRD. In ARDS, symptoms develop over days, 
however, there is no gold standard diagnostic test and therefore statistical tests for 
association to ARDS will not be entirely accurate. In an attempt to work around these 
problems, surrogate markers or surrogate endpoints are often used. These markers 
are either easier to measure or they can be measured earlier in the disease process. In 
the study of CKD treatment, proteinuria is often used but proteinuria describes only 
one aspect of kidney function; and using eGFR decline as an outcome may be 
problematic where some subjects are already progressing faster than others (Stevens 
et al., 2006). In ARDS, using mortality or ventilator-free days as an outcome may be 
easier than an ARDS diagnosis because of the difficulties in reaching a diagnosis, as 
discussed earlier (section 1.2.2). 
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1.3.6.3 Other Issues 
NMR is generally assumed to be more reproducible than LC-MS, but the situation 
may not be as simple as previously thought. Sample preparation is simpler in NMR, 
and this should lead to less variability, but because enzymes can potentially still be 
active in serum and plasma samples, changes can still occur. In untreated serum and 
plasma samples, proteins bind specific metabolites, including, lactate, citrate, 
phenylalanine, tyrosine, histidine and pyruvate (Jupin et al., 2013, Nicholson and 
Gartland, 1989). However, research has shown that this binding can be changed by 
fatty acids, simple dilution, and even TSP (Barrilero et al., 2017, Jupin et al., 2014). 
Much NMR-based metabolomics work is now carried out in samples after protein 
extraction, or after ultrafiltration, to remove baseline problems, and although 
metabolites are also lost during this process, the simplification may be worthwhile. 
In metabolomics, the identification of peaks in NMR or MS spectra is extremely time 
consuming. This results in significant peaks being labelled as unknowns, or worse, 
in incorrect labelling of peaks, which then leads to even more problems in validating 
results and replicating findings. 
Finally, general sampling issues can be as problematic here as in other areas of 
medical research. Serum or plasma may not be able to differentiate between groups, 
and other biofluids could be tested. If research is based upon samples taken at one 
specific timepoint, they may not be comparable to samples taken at a different point 
in the disease process. 
 
1.3.6.4 Potential Solutions 
There are many statistical problems with ‘omics’ studies. A simple method to reduce 
false positive findings would be to lower the p-value, for example, simply lowering 
the p-value to 0.005 would reduce the chance of type I errors (Ioannidis, 2018). But 
this would also increase the risk of false negatives (type II errors), and would 
probably be better handled with other statistical methods, such as the false discovery 
rate (Benjamini and Hochberg, 1995) or Bayesian methods. Following up untargeted 
studies with targeted studies is also a way to address these issues, and larger studies 
or meta-analyses can also help can also help validate findings. 
Elucidating causal mechanisms and biological meaning is a logical next step to 
‘omics’ studies, which can help to evaluate research findings, and this can be carried 
out in many ways. Pathway analysis can be used to fit multiple metabolites, or 
findings from different ‘omics’ methodologies, together. One of the methods used 
here is known as enrichment analysis, where algorithms are given the list of up- and 
down-regulated metabolites, and attempt to find the affected pathways. One 
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limitation of this approach is that metabolite pathways have to be known in advance, 
which makes it impossible to find new pathways, whilst another is that it is difficult 
to use across species. Examples of tools that include enrichment analysis are 
Metscape and MetaboAnalyst (Karnovsky et al., 2012, Xia and Wishart, 2011). 
Another method is to use isotopic labelling of metabolites to trace the route of a 
metabolite of interest, and elucidate which pathways are affected. The pathways 
found through these experiments are often more complex than initially thought 
(Baverel et al., 2003). 
It is also possible to use the spectra for classification with no knowledge of the 
metabolites or pathways involved, and in our data-driven age, perhaps this will 
become the predominant method. This would, however, require extremely well 
validated models and rigorous statistical testing. 
 
1.3.7. SUMMARY 
Technologies such as NMR and MS, combined with statistical approaches and 
computer processing, have enabled metabolomics to be applied in many different 
areas. Much recent work has been focused on identifying biomarkers of early disease, 
so that diagnosis can be made earlier, or progression can be tracked, and so that 
treatment can be targeted. 
In CKD, there are many articles that have attempted to identify as many uremic 
retention solutes as possible using the new techniques, but these compounds may or 
may not be related to disease progression, and may or may not be a result of reduced 
kidney function. The sheer number of metabolomics articles appearing, along with 
the huge number of significant metabolites open up the ‘omics’ fields to valid 
criticism. The lack of consensus and small number of replication studies is 
disheartening, which suggests that biochemical pathways are more complex than 
currently understood, that there are more sources of variability than we can currently 
measure, and that conventional statistics has difficulties when applied to ‘omics’ 
studies. 
In ARDS, most ‘omics’ studies have been based on proteomics. However, more 
metabolomics studies are emerging, including some based upon exhaled breath. As 
with CKD, there is still a lack of consensus, and the heterogeneity of ARDS is partly 
responsible for this. This issue could be resolved with a suitable biomarker which, if 
validated, could help to subcategorise patients clinically, as well as improving ARDS 
research.  
Statistical issues are a major problem for all ‘omics’ fields, and several experimental 
problems have to be considered. However, ‘omics’ studies are generally hypothesis 
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CHAPTER 2. AIMS 
The aim of the main study (papers I and IV) was to apply NMR-based metabolomics 
methods to a 5/6 nephrectomy rat model of CKD established at Aarhus University. 
A pilot project allowed Dr Martin Skøtt and myself to establish and test protocols, 
especially in relation to urine collection in cooled vials and the organs it was possible 
to obtain. Thus, the aim of the main experiment was to find metabolite differences in 
urine, serum and tissue between the 5/6 nephrectomy rat model of CKD and sham-
operated rats. The analysis of different types of samples was expected to be beneficial 
in explaining the origin of the metabolite changes and the underlying pathological 
mechanisms. 
As the 5/6 nephrectomy experiment progressed, and particularly after examining 
spectra where repeated spectral acquisition was necessary, we realised that the 
repeated spectra occasionally had marked differences to the original spectra. This led 
us to investigate all reanalysed samples in two of the large experiments carried out 
by Dr Raluca Maltesen (Buggeskov et al., 2018, Maltesen et al., 2017). The aim of 
this study, presented in paper II, was to characterise some of the spectral differences 
in reanalysed samples. 
A metabolomics study on lung injury (paper III) was started prior to the rat CKD 
experiments. This was based upon serum samples collected by Professor Bodil Steen 
Rasmussen from a cohort of patients undergoing elective coronary artery bypass 
grafting with cardiopulmonary bypass. Working in collaboration with Dr Raluca 
Maltesen, the aim here was to detect early metabolite differences in patients that went 
on to develop hypoxaemia, to investigate the underlying processes, and to test 




CHAPTER 3. MATERIALS AND 
METHODS 
The following sections will describe the methods in detail and attempt to make 
sample and NMR details easily comparable. The 5/6 nephrectomy rat CKD model is 
the subject of papers I and IV, whilst papers II and III are based upon samples taken 
from humans at risk of hypoxaemia following cardiac surgery.  
 
3.1. PAPERS I + IV – TISSUE, URINE AND BLOOD METABOLITE 
SIGNATURES OF CHRONIC KIDNEY DISEASE IN THE 5/6 
NEPHRECTOMY RAT MODEL 
3.1.1. ANIMAL MODEL AND SAMPLE COLLECTION 
The 5/6 nephrectomy model was used because of extensive local expertise at The 
Water and Salt Research Centre, Aarhus University (Kwon et al., 1998). As described 
in the introduction (section 1.1.6), the 5/6 nephrectomy model is known to suffer 
from progressive chronic kidney disease, with clinical and histopathological 
similarities to human CKD. An addition to this model was the implantation of a 
suprapubic catheter, to enable the intermittent collection of urine for short durations, 
without using metabolic cages. Animal experiments were approved by the Danish 
Ministry of Justice, and conducted in accordance with the National Institute of Health 
“Guide for the Care and Use of Laboratory Animals” (8th edition). 
Thirty male Wistar rats (Taconic, Ejby, Denmark) were randomised to either 5/6 
nephrectomy (Nx) or sham operation. More rats were randomised to the nephrectomy 
group (n=17), compared to the sham operation group (n=13), as more nephrectomy 
rats were expected to die due to the more extensive surgical procedure. On day -7 
(week -1 in Figure 13), rats were anaesthetised with isoflurane (Abbott Scandinavia, 
Solna, Sweden), placed on a heating pad to maintain body temperature, and after 
shaving and disinfection, a midline incision was made. Dissection and bimanual 
manipulation were used to reveal the left kidney, and after dissecting the kidney 
capsule carefully, without damaging the adrenal gland, the two poles were tied off. 
Sham-operated rats did not have the kidney poles removed. Haemostasis was aided 
with swabs, the muscle and skin layers were closed separately, and buprenorphine 
(Reckitt Benckiser, Slough, UK) was administered subcutaneously for pain control. 
Buprenorphine was also administered in the drinking water for three days. On day 0, 
rats were anaesthetised, the midline incision was reopened, and dissection was 
directed towards the right flank. The right kidney was exposed, dissected free from 
NMR-BASED METABOLOMICS IN KIDNEY AND LUNG DISEASE 
56 
the capsule, being careful not to damage the adrenal gland, and then the renal artery 
and vein were tied off. Sham-operated rats did not have the right kidney removed. 
Closure and analgesia were performed as described above. 
 
Figure 13. Sample collection protocol illustrating when urine (U), serum (S), and tissue (T) 
samples were obtained in relation to surgery. 
Urine samples were collected by attaching the implanted catheter to a silicone tube, 
the other end of which was attached to an Eppendorf tube suspended in a container 
of ice and water. The rats were placed in restraining cages for approximately two 
hours, with free access to water, whilst urine was collected. The restraining cages 
were made at Aarhus University by Mogens Koed, and were used instead of 
metabolic cages (which require three days of isolation, and where urine is easily 
contaminated by faeces). Another advantage of the restraining cage was that urine 
could be collected and cooled immediately, to reduce bacterial metabolism and 
evaporation. Urine was then centrifuged to remove precipitate, before aliquoting, 
freezing in liquid nitrogen, and storage at -80 °C. 
Blood samples were collected from the tail veins, or cardiac puncture at sacrifice. 
Samples were left to clot at room temperature for 30 minutes before being spun down. 
Serum was then aliquoted and snap frozen in liquid nitrogen. Tissue samples were 
collected after sacrifice, weighed, placed in cryo-tubes and snap frozen in liquid 
nitrogen. Both serum and tissue samples were stored at -80 °C. 
 
3.1.2. SAMPLE PREPARATION AND NMR ANALYSIS 
Urine and blood samples were defrosted at 4 °C. They were then vortexed briefly 
before centrifuging (at 14000 x g and 4 °C for 5 minutes), to remove precipitate. 
Samples were mixed with buffer, 9:1 urine:buffer (1.5 M KH2PO4, 2 mM NaN3, 0.1% 
TSP, pH* 7.4) or 1:1 serum:buffer (0.075 M NaH2PO4, 0.04% NaN3, 0.08% TSP, 
pH* 7.4), to keep the pH stable, and to provide a lock signal for the NMR 
spectrometer. Because rat urine samples often suffered from precipitation after the 
addition of buffer, samples were re-centrifuged before transferring to an NMR tube. 
-1 6543210







+ catheter implantation 
Right total nephrectomy 
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Tissue samples were freeze-dried (lyophilised) and then homogenised using a 
Precellys bead homogeniser (Bertin Instruments, Montigny-le-Bretonneux, France). 
50 mg or 100 mg of the homogenised tissue was extracted using ice-cold methanol, 
chloroform and water in a 2:2:1.8 ratio (Bligh and Dyer, 1959, Lin et al., 2007). The 
hydrophilic phase was transferred to a clean vial, lyophilised, and then dissolved in 
0.1 M imidazole-d4 buffer (0.02% NaN3, 1 mM TSP, pH* 7.4).  
NMR spectra were recorded on a Bruker 600 MHz Avance DRX-600 equipped with 
a TXI probe (Bruker BioSpin, Rheinstetten, Germany). Serum spectra were acquired 
with the 1D nuclear Overhauser effect spectroscopy (NOESY), Carr-Purcell-
Meiboom-Gill (CPMG) (Carr and Purcell, 1954, Meiboom and Gill, 1958), and 
skyline projection of J-resolved (pJRES) (Aue et al., 1976) pulse sequences. NMR 
spectra of urine and tissue samples were also acquired using the NOESY, CPMG and 
pJRES pulse sequence, but because quantification of metabolites was one of the aims, 
a quantitative 1D NOESY spectrum was also run using a long relaxation delay. NMR 
experimental details are listed in Table 2. 
 1D NOESY 1D CPMG J-resolved 
Bruker pulse 
sequence 
noesygppr1d cpmgpr1d jresgpprqf 
Temperature 310 K (serum) 
298 K (urine + tissue) 
310 K (serum) 
298 K (urine) 
310 K (serum) 
298 K (urine + tissue) 
Number of scans 128 
64 (qNOESY) 
128 4 (per increment) 
Data points (time 
domain) 
98304 (serum) 
65536 (urine + tissue) 
65536 Direct dimension: 16384 
Indirect dimension: 42 
Spectral width 30 ppm (serum)  
20 ppm (urine + 
tissue) 
20 ppm Direct dimension: 12 ppm 
Indirect dimension: 54 Hz 
Acquisition time 2.73 s 2.73 s 1.17 s 
Receiver gain 90.5 (serum + urine) 
203 (tissue) 
90.5 (serum + urine) 64 (serum + urine) 
203 (tissue) 
Relaxation delay 4 s  
27.3 s (qNOESY) 
4 s 4 s 
B1 field strength 17 Hz (serum) 
22 Hz (urine) 
20 Hz (tissue) 
17 Hz (serum) 
22 Hz (urine) 
20 Hz (tissue) 
17 Hz (serum) 
22 Hz (urine) 
20 Hz (tissue) 
Spectral size 131072 131072 Direct dimension: 32768 
Indirect dimension: 64 









Manual phase and 
baseline correction 
Manual phase and 
baseline correction 
Tilt, symmetrise, skyline 
projection and baseline 
correction 
Table 2. Acquisition details for 5/6 nephrectomy serum, urine and tissue NMR spectra. 
NOESY, 1D nuclear Overhauser effect spectroscopy; CPMG, Carr-Purcell-Meiboom-Gill. 
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Two-dimensional NMR spectra were also acquired, to enable metabolite 
identification, using the 1H,13C-HSQC (heteronuclear single quantum coherence) and 
1H,1H-TOCSY (total correlation spectroscopy) pulse sequences. 
 
3.1.3. MULTIVARIATE AND UNIVARIATE ANALYSIS 
Urine NMR spectra were either normalised to the creatinine integral or to total 
intensity, because of large concentration differences between the nephrectomy and 
sham-operated rats. Regional alignment was also necessary in the urine spectra, 
presumably because of divalent cation concentration differences, and was performed 
using the icoshift algorithm (Savorani et al., 2010). Blood and tissue NMR spectra 
were normalised to an external PULCON (pulse length based concentration 
determination) signal (Wider and Dreier, 2006). Processing steps are described in 
Table 3. 
 Urine Serum Tissue 
Spectra used for 
multivariate 
analysis 
CPMG (NOESY spectra 
baselines poor due to 
proteinuria) and pJRES 
CPMG and pJRES NOESY and pJRES 
Reference TSP-d4 α-Glucose TSP-d4 
Water region 
removed 
4.6-5.0 ppm 4.5-4.9 ppm Not performed 
icoshift regions 58 4 Not performed 
Normalisation Total intensity or 
creatinine integral 
normalisation 
PULCON TSP and extracted 
freeze-dried tissue 
mass 
Bin width 0.001 ppm 0.001 ppm 0.001 ppm 
Centring Mean centring Mean centring Mean centring 
Scaling Pareto scaling Pareto scaling Pareto scaling 
Cross validation Random 10 segment cross 
validation with 10 
iterations  
Random 10 segment 
cross validation with 
10 iterations 
Random 10 segment 
cross validation with 
10 iterations 
Table 3. Processing details for NMR spectra. NOESY, 1D nuclear Overhauser effect 
spectroscopy; CPMG, Carr-Purcell-Meiboom-Gill; pJRES, skyline projection of J-resolved 
spectrum; PULCON, pulse length based concentration determination. 
Principal component analysis (PCA) and partial least squares discriminant analysis 
(PLSDA) were carried out using PLS-Toolbox v6.5 (Eigenvector Research, 
Washington, USA) and MATLAB v8.3 (Mathworks, Massachusetts, USA). Cross 
validation was performed, with 10 iterations of 10 random segments, to ensure that 
models were robust, to select model parameters, and to identify outlying samples. 
Significant peaks were identified using the loadings plots and Variable Importance 
in Projection (VIP) scores (Chong and Jun, 2005). These were then integrated, after 
local baseline correction, using peak fitting methods on the quantitative spectra in 
MestReNova v8.1 (Mestrelab Research, Santiago de Compostela, Spain). Where 
peak overlap was problematic, an alternative peak for the same metabolite was used, 
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or pJRES spectra were used. No quantitative spectra were recorded for serum 
samples, because of the lipoprotein baseline, and all integrals obtained from non-
quantitative spectra are reported as concentration relative to the largest measured 
value. 
Univariate analysis was carried out in SPSS v23 (IBM Corporation, New York, 
USA), with linear mixed-effects models to analyse urine metabolites over the entire 
testing period; t-tests or Mann-Whitney U tests for the final tissue and serum samples; 
and ANOVA for the final kidney samples, where there were two sham operation 
kidneys, but only one 5/6 nephrectomy kidney. A Holm-Bonferroni corrected p-value 
threshold of 0.05 was used for multiple testing. 
 
3.2. PAPER II – CITRATE NMR PEAK IRREPRODUCIBILITY IN 
BLOOD SAMPLES AFTER REACQUISITION OF SPECTRA 
3.2.1. SAMPLE CHARACTERISTICS AND NMR ANALYSIS 
On a few occasions during the first experiment, we noticed that some metabolite 
integrals, and in particular the citrate signals, had a different intensity in the repeated 
NMR spectrum. This led us to an investigation of all the repeated spectra in two large 
metabolomics studies carried out by Dr Raluca Maltesen, one on serum samples, and 
the other on plasma samples. Both experiments had already received ethical approval 
from the local ethics committees. The serum samples were collected as part of an 
experiment looking at lung injury following coronary artery bypass graft surgery (see 
section 3.3 below), and the plasma samples were collected during a randomised 
controlled trial of lung protection strategies during surgery involving 
cardiopulmonary bypass (Buggeskov et al., 2018, Maltesen et al., 2016, Maltesen et 
al., 2017). Sample preparation and NMR analysis were almost identical for both 
projects, the only difference being that the serum buffer included 1,1,2,2,3,3-
hexadeutero-4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA-d6) as 
an internal standard (details in Table 4). There were over 700 samples for each 
experiment, and a total of 44 serum and 81 plasma samples were reanalysed within 
48 hours of the original spectrum being acquired. 
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 Lung Injury Pulmonary Protection Trial 
Sample type Serum EDTA plasma 
Collection 
protocol 
Pulmonary artery or left atrial 
catheter. 30-45 minutes clotting time 
at room temperature followed 
immediately by centrifugation, 
aliquoting and storage at -80 °C. 
Pulmonary artery catheter. Samples 
immediately centrifuged at 4 °C. 




Thawed at 4 °C (fridge) for 30 
minutes, and kept on ice whilst 
preparing NMR samples. 
Thawed at 4 °C (fridge) for 30 
minutes, and kept on ice whilst 
preparing NMR samples. 
NMR buffer 2:1 serum:buffer 
(0.2M phosphate buffer, 0.3mM 
DSA-d6, pH* 7.4) 
2:1 plasma:buffer 




Temperature 298.1 K 298.1 K 
Number of scans 256 128 
Data points (time 
domain) 
32768 32768 
Spectral width 20 ppm 20 ppm 
Acquisition time 2.73 s 2.73 s 
Receiver gain 173.2 173.2 
Relaxation delay 4 s 4 s 
B1 field strength 31 Hz 37 Hz 
Spectral size 131072 131072 
Window function Exponential multiplication (0.3 Hz) Exponential multiplication (0.3 Hz) 
Other processing 
steps 
Manual phase and baseline 
correction 
Manual phase and baseline 
correction 
NMR reference Alanine CH3 duplet Alanine CH3 duplet 
Normalisation PULCON PULCON 




within 48 hours 
44 81 
Table 4. Sample collection details, and NMR acquisition and processing details. NOESY, 1D 
nuclear Overhauser effect spectroscopy; CPMG, Carr-Purcell-Meiboom-Gill; pJRES, skyline 
projection of J-resolved spectrum; PULCON, pulse length based concentration determination; 
pH*, apparent pH uncorrected for D2O. 
 
3.2.2. INTEGRATION AND STATISTICAL ANALYSIS 
To ensure precision, two peaks (or two regions) for each of the metabolites citrate, 
lactate, phenylalanine, histidine and glucose were integrated. These metabolites have 
previously been reported to bind to protein, except for glucose, which was used as a 
control. Manual or automatic baseline correction was performed using MestReNova 
v12 (Mestrelab Research S.L., Santiago de Compostela, Spain), and where these 
methods did not work well, the Global Spectral Deconvolution tool was used. Two 
graphs were plotted for each metabolite: a comparison of the integral of the two peaks 
(Inta vs Intb); and a comparison of the percentage difference in integrals between the 
original and reanalysed spectrum for both peaks (ΔInta(%) vs ΔIntb(%), as defined in 
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Equation 5). These comparisons were made to find changes that occurred 
reproducibly in both peaks for each metabolite. ANOVA was used to assess the 
statistical significance of linear fitting, and a p-value of less than 0.05 was considered 





Equation 5. Integral percentage difference formula. 
To investigate some of the possible causes of these changes, clinical factors, 
lipoprotein integrals and EDTA integrals were analysed and plotted against 
metabolite percentage changes. 
 
3.3. PAPER III – PREDICTIVE BIOMARKERS AND METABOLIC 
HALLMARK OF POSTOPERATIVE HYPOXAEMIA 
3.3.1. PATIENT AND SAMPLE CHARACTERISTICS 
The patient group studied were originally part of a study of the effects of coronary 
artery bypass grafting (CABG) involving cardiopulmonary bypass (on-pump CABG) 
on post-operative oxygenation. The research was approved by the local ethics 
committee, and patients provided informed consent. All patients underwent elective 
(i.e. non-emergency) CABG surgery and serum samples were collected from two 
catheters, one ‘before’ the lungs in the pulmonary artery (PA) and the other ‘after’ 
the lungs in the left atrium (LA). Serum samples were obtained at seven different 
timepoints: before CPB (but after sternotomy) and at 0, 2, 4, 8, 16 and 20 hours after 
weaning from CPB. We decided to concentrate on the samples taken 16 hours after 
weaning from CPB, as this would be far enough from surgery, but before ARDS is 
normally diagnosed, and a total of 47 patients had both LA and PA samples at this 
point. All blood samples were taken and prepared by the same person, Professor 
Bodil Steen Rasmussen, and serum samples were allowed to clot at room temperature 
for 30 minutes before centrifugation at 3000 rpm for 10 minutes. Aliquots were stored 
at -80 °C. 
All patients were being treated with statins (one of the inclusion criteria) and were 
over 18 years old, whilst treatment with immune suppressors or steroids were 
exclusion criteria. All patients had decreased blood oxygen levels on the second and 
third postoperative days. Arterial blood gas (ABG) measurements at 72 hours, which 
were carefully controlled and taken after breathing atmospheric air for 10 minutes, 
were used to classify patients into a severely hypoxaemic group (PaO2/FiO2 < 30 
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kPa), a mildly hypoxaemic group (30 kPa ≤ PaO2/FiO2 ratio < 40 kPa) and an 
unaffected group (PaO2/FiO2 ratio ≥ 40 kPa). Patient details are listed in Table 5.  
 Severe hypoxaemia Mild hypoxaemia Unaffected 
n 9 23 15 
Age (years) 64.7 ± 10.6 65.5 ± 10.7 66.1 ± 7.9 
Male gender 5 18 15 
BMI 27.6 ± 4.6 26.9 ± 4.5 27.4 ± 2.7 
Diabetes mellitus 4 6 4 
Smoker 5 6 4 
COPD 3 2 3 
PaO2/FiO2 at 72 
hours (kPa) 
26.5 ± 2.1 35.7 ± 2.3 43.6 ± 2.8 
Table 5. Patient characteristics reported as mean ± standard deviation, or number in group. 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; PaO2, partial pressure 
of oxygen in blood; FiO2, percentage of oxygen in inspired air. 
 
3.3.2. SAMPLE PREPARATION AND NMR ANALYSIS 
As for the CKD experiment, serum samples were thawed at 4 °C before vortexing 
and centrifuging to remove precipitate. Samples were mixed with 0.2M phosphate 
buffer (pH* 7.4 in D2O) in a 2:1 (sample:buffer) ratio before transferring to a 5mm 
NMR tube. NMR spectra were recorded on a Bruker 600 MHz Avance DRX-600 
equipped with a TXI probe (Bruker BioSpin, Rheinstetten, Germany). 
 1D CPMG 
Bruker pulse sequence cpmgpr1d 
Temperature 310.1 K 
Number of scans 128 
Data points (time domain) 32768 
Spectral width 12 ppm 
Acquisition time 2.28 s 
Relaxation delay 2 s 
B1 field strength 26.6 Hz 
Spectral size 65536 
Window function Exponential multiplication (0.3 Hz) 
Other processing steps Manual phase and baseline correction 
NMR Reference Lactate duplet 
Table 6. NMR acquisition and processing details. CPMG, Carr-Purcell-Meiboom-Gill. 
Two-dimensional spectra were also recorded on representative samples to enable 
identification of metabolites. Three types of spectra were acquired: 1H,13C-HSQC 
(heteronuclear single quantum coherence), 1H,1H-TOCSY (total correlation 
spectroscopy), and J-resolved spectra. 
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3.3.3. MULTIVARIATE AND UNIVARIATE ANALYSIS 
NMR spectra were normalised using the lactate peak area and lactate concentration 
measured at the same timepoint in another sample. The water region (4.5-4.8 ppm) 
was removed, before dividing the spectra into 0.001 ppm width bins, and two scaling 
methods were tested, log transformation and auto-scaling. 
PCA, PLS and PLS-DA modelling were carried out using PLS-Toolbox v6.5 
(Eigenvector Research, Washington, USA) and MATLAB v7.13 (Mathworks, 
Massachusetts, USA). PLS models were built using the 72 hour (day 3) postoperative 
PaO2 values, and PLS-DA models were constructed using mild vs unaffected and 
severe vs unaffected comparison groups. Both Monte Carlo cross validation and 
permutation testing were used, with 5000 iterations of cross validation where 70% of 
the data was used to train the model, and 30% to assess the model; and 500 
permutations of group labels. Receiver operating characteristic (ROC) curve analysis 
was also used to assess the potential diagnostic performance of the PLS-DA models. 
Significant metabolites were identified using the loadings plots and VIP scores. Peaks 
were integrated using the multi-integration tool in AMIX v 3.9.10 (Bruker BioSpin, 
Rheinstetten, Germany) 
Univariate analysis was carried out in SPSS v22 (IBM Corporation, New York, 
USA), with Shapiro-Wilk normality testing followed by either t-tests or Mann-
Whitney U tests, when comparing two groups, and ANOVA or Kruskal-Wallis H 





CHAPTER 4. RESULTS AND 
DISCUSSION 
This thesis is comprised of four papers, based upon the 5/6 nephrectomy rat model 
of CKD, and human studies on patients suffering from hypoxaemia following cardiac 
surgery. In this section the results will be briefly presented, and the discussion 
presented in the papers will be expanded, concentrating on the following areas: 
possible pathways and pathological mechanisms, limitations of the studies, statistical 
and ‘omics’ issues, and potential further work. 
 
4.1. PAPERS I + IV – TISSUE, URINE AND BLOOD METABOLITE 
SIGNATURES OF CHRONIC KIDNEY DISEASE IN THE 5/6 
NEPHRECTOMY RAT MODEL 
There are two aspects of the experimental work in this paper that should be noted. 
Firstly, lung, heart, liver, spleen and kidney tissues, as well as urine and serum, were 
analysed. Although the analysis of tissue is difficult in humans, it is also relatively 
rare in animal models, and connecting serum and urine changes with tissue changes 
allowed us to investigate some of the origins of the altered metabolites and suggest 
hypotheses of disease mechanisms. Secondly, we analysed urine from multiple 
timepoints using mixed models, with the aim of being able to analyse differences due 
to 5/6 nephrectomy, whilst also handling the variability between individuals. 
 
4.1.1. SUMMARY OF RESULTS 
Hospital laboratory measurements confirmed that serum urea and creatinine 
concentrations were higher in the 5/6 nephrectomy rats, in keeping with CKD, and 
other articles have shown that histological, urine and blood changes in the 5/6 
nephrectomy kidney are also similar to human CKD (Gadola et al., 2004, Maddox et 
al., 1986). We expected more rats from the 5/6 nephrectomy group to suffer surgical 
complications, because of the more extensive surgery, but three rats from each group 
passed away before the experiment could be completed. Polyuria was also evident in 
the 5/6 nephrectomy rats, although timed urine volume was not measured.  
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Figure 14. (A) Example NMR spectra of urine. (B) PCA scores plot showing sham-operated 
and 5/6 nephrectomy (Nx) urine spectra. (C) PCA scores plot (same as panel B) coloured by 
sample week. Metabolite annotations are as follows: 1, lactate; 2, alanine; 3, acetate; 
4, succinate; 5, oxoglutarate; 6, citrate; 7, dimethylamine; 8, dimethylglycine; 9, creatinine; 
10, taurine; 11, betaine; 12, trimethylamine oxide; 13, hippurate; 14, allantoin; 15, urea; 
16, formate. Reproduced with permission (Hanifa et al., 2019). Copyright (2019) Springer 
Nature.  
NMR spectra revealed differences between 5/6 nephrectomy and sham-operated rats, 
but were very complex when examined visually. This was especially true for urine 
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(Figure 14A). Multivariate analysis was able to differentiate sham-operated and 
nephrectomy rats, using unsupervised PCA modelling on urine (from week 1 
onwards, Figure 14B+C), and supervised PLS-DA on tissue and serum (week 6 
samples). Quantification enabled the investigation of individual metabolites, and 
allantoin was the most widely affected metabolite, being significant in all 
compartments. In tissues, significant metabolites included: asparagine, creatine, 
dimethylamine, dimethylglycine, hippurate, trigonelline and trimethylamine. Whilst 
in urine or serum, benzoate, citrate, dimethylglycine, fumarate, guanidinoacetate, 
malate, myo-inositol and oxoglutarate were significant. 
Whereas all of these metabolites have previously been found to be significant in 
animal models of CKD, or small-scale human studies, not all are generally accepted 
as CKD metabolites in humans, for example allantoin and citrate are not listed in the 
EuTox database (Duranton et al., 2012). However, one of the difficulties with a long 
list of statistically significant metabolites is finding the connections and pathways 
linking different metabolites. This is not a simple task given the multitude of 
biochemical pathways and our current limited, but growing, knowledge of these 
pathways. The following subsections will attempt to put some of these findings into 
context and discuss the possible connections between them. 
 
4.1.2. ALLANTOIN AND OXIDATIVE STRESS 
As discussed in the 5/6 nephrectomy paper, allantoin concentrations were 
significantly higher in serum and all sampled tissues from 5/6 nephrectomy rats. 
Urine concentrations were also higher, although this was not significant after 
correction for multiple testing. Allantoin has been mentioned sporadically in the 
CKD literature for almost a century, for example early research in rats found that 
both the liver and kidneys were required for production of allantoin from urate, and 
the subsequent excretion of allantoin in the urine (Byers et al., 1947). But, whereas 
the review written by Zhao (Zhao, 2013) reports allantoin as a CKD biomarker, based 
upon rat studies, the EUTOX review from 2012 (Duranton et al., 2012), based on 
human studies, does not mention it. The lack of early human studies finding allantoin 
as significant could be due to the fact that humans lack the urate oxidase (uricase) 
enzyme, which converts uric acid to allantoin (Figure 15), but there have been more 
recent positive findings in human studies. For example, in a study by Kand’ar and 
Zakova (2008), increased allantoin levels were found in red blood cells (erythrocytes) 
and plasma from human patients with CKD, and in another paper, increased allantoin 
concentrations in patients with ESRD were linked to oxidative stress or bacterial 
metabolism (Rhee et al., 2010). The most compelling evidence is the link to mortality 
in human CKD found in the 2018 paper by Hu et al., where allantoin was one of three 
metabolites (the others being fumarate and ribonate) associated with mortality in 
human CKD (Hu et al., 2018). The link between mortality and allantoin 
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concentrations measured years in advance, across two large independent study 
populations, is good evidence that allantoin is a significant metabolite in humans. 
Another point to note is that the studies by Hu et al. and Rhee et al. were based on an 
LC-MS metabolomics platform, whilst ours was based on an NMR platform, 
suggesting that the findings are consistent across different analytical platforms. 
 
Figure 15. Purine breakdown pathway illustrating the conversion of guanosine, inosine and 
adenosine to uric acid and eventually allantoin. XO, xanthine oxidase (which can be reversibly 
converted to xanthine dehydrogenase). *The uricase enzyme is not present in humans, and this 
step is therefore thought to be the result of reactive oxygen species. 
Whether allantoin or one of its precursors has a causal link to declining renal function 
or mortality, or is only a statistical association, will hopefully be revealed by further 
research. A large amount of work, however, has and is being carried out on urate and 
xanthine oxidase. Urate concentrations did not correlate with allantoin concentrations 
in the study by Hu et al. (2018), and the literature currently offers a mixed picture of 
the benefits of reducing xanthine, uric acid and allantoin concentrations with xanthine 
oxidase inhibitors such as allopurinol. In one study, patients with CKD had lower 
uric acid concentrations and a slower progression of disease when taking allopurinol, 
as well as a reduced risk of cardiovascular events (Goicoechea et al., 2010). However, 
a retrospective study showed that high urate concentrations were associated with 
lower mortality in patients with ESRD (Kim et al., 2017). Another study on patients 
with gout showed that they had higher plasma allantoin levels than controls, and 
although treatment with allopurinol reduced allantoin levels, they were still higher 
than controls (Stamp et al., 2014). And increased xanthine oxidase activity (which 
itself can produce strong oxidants), has been described in ESRD (Choi et al., 2011, 
Rhee et al., 2010). 
Humans lack the uricase enzyme to convert uric acid to allantoin, and it has been 
hypothesised that mutations in the uricase gene increased urate concentrations in 
humans in comparison to other mammals, which helped protect humans against 
oxidative damage (Ames et al., 1981). It is also generally accepted that allantoin in 
human samples is the result of urate oxidation by reactive oxygen species (Caussé et 
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also be considered, and the most obvious is accumulation due to reduced renal 
function. Greger et al. stated that allantoin is handled similarly to inulin, and therefore 
increased serum concentrations are, at least partly, due to retention after nephrectomy 
(Greger et al., 1975). However, Pordy et al. stated that allantoin could not simply 
diffuse across lipid bilayers, and Kand’ár and Záková showed that red blood cell and 
plasma allantoin levels did not correlate in patients with CKD, both suggesting that 
the elevated levels we found in all tested organs were not simply due to diffusion 
down concentration gradients (Kand'ár and Záková, 2008, Pordy et al., 1987). 
Increased uricase activity could also be a cause in rats, but uricase is mainly located 
in the liver and would not explain the changes in other tissues. Increased purine 
turnover, not necessarily due to oxidative stress, could also lead to higher 
concentrations of allantoin (Fisher-Wellman and Bloomer, 2009, Johnson et al., 
1989). Dietary sources should also be considered, as uric acid levels have been linked 
to high-fructose diets and metabolic syndrome (Nakagawa et al., 2006), though this 
is not likely to be relevant in animal experiments. And changes in the gut microbiome 
could also been be linked, via altered uricase activity, to allantoin concentrations 
(Wong et al., 2014). 
Oxidative stress is a very difficult subject to study because the reactive oxygen 
species (ROS) have very short half-lives, reacting with cell components and causing 
damage very quickly, and they are therefore very difficult to quantify directly. This 
leads to many proxy markers being used in the literature, such as antioxidants, e.g. 
glutathione and vitamin C; or damaged cell components, e.g. lipid peroxides or DNA 
base oxidation products. Also, many of these biomarkers are new, and therefore 
normal concentration ranges have not yet been developed. Ideally, it would be 
possible to quantify multiple proxy markers to find a better measure of oxidative 
stress. In our study we found that glutathione concentrations were slightly higher in 
the heart tissue of CKD rats, and although this was not statistically significant, it 
could be evidence of oxidative stress in the heart. In an adenine-induced rat model of 
CKD, glutathione was also found to be increased in the CKD heart, but decreased in 
the CKD kidney (Velenosi et al., 2016); whilst a study in humans found reduced 
levels of glutathione in more advanced stages of CKD (Ceballos-Picot et al., 1996). 
Together with the allantoin findings, changes in glutathione could suggest that ROS 
may be a factor in the development of the consequences of CKD in diverse organs. 
In summary, oxidative stress is a recognised pathological mechanism in CKD, and 
could be an important link between the kidney and other organ systems, for example, 
it is potentially a risk factor for cardiovascular disease (Ling and Kuo, 2018). If 
allantoin can be measured in blood or urine at an early stage of human CKD, and the 
connection to later morbidity and mortality made, it could prove to be an important 
biomarker. 
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4.1.3. THE GUT-KIDNEY AXIS 
Many metabolites derived from the diet or via gut bacteria have been implicated in 
CKD. Indoxyl sulfate, a metabolite produced from dietary tryptophan, and p-cresyl 
sulfate, produced from dietary tyrosine, have been widely investigated as uremic 
retention solutes. Benzoate is a natural part of the diet which is also produced by gut 
bacteria, and converted to hippurate in the liver. Indoxyl sulfate, p-cresyl sulfate and 
hippurate accumulate in CKD and all are difficult to control with conventional 
haemodialysis, because they are highly protein bound (Sirich et al., 2014). Tubular 
transport mechanisms, as opposed to glomerular filtration, are therefore required to 
clear these metabolites from the circulation. As mentioned previously, GFR 
measurement only assesses one aspect of kidney function, and these metabolites 
could therefore be used to assess tubular function. Unfortunately, although the 
shortcomings of GFR assessment are widely known, it has been difficult to move the 
focus of measurement and diagnosis elsewhere. Assessing others axes of kidney 
function could help to detect disease earlier, subdivide kidney disease, risk stratify 
patients, and suggest new treatment targets. Several of these metabolites are also 
known to accumulate in kidney tissue via the organic anion transporters (OATs), and 
this is thought to be part of the mechanism causing further damage to the kidneys 
(Enomoto and Niwa, 2007, Wikoff et al., 2011). 
In paper I, we found higher concentrations of hippurate in 5/6 nephrectomy kidneys, 
and lower concentrations of benzoate in 5/6 nephrectomy urine. Hippurate 
concentrations in 5/6 nephrectomy urine were also increased, although this was not 
statistically significant. Because both metabolites are in the same pathway, but seem 
to react differently to 5/6 nephrectomy, we proposed that a ratio of hippurate and 
benzoate in the urine could be a sensitive biomarker. We could not test this on the 
samples in the study because benzoate levels were often below the limit of detection, 
especially in the 5/6 nephrectomy rats, but it could be worth exploring (Figure 16). 
In a similar study to ours, elevated concentrations of all three metabolites (indoxyl 
sulfate, p-cresyl sulfate and hippurate) were reported in tissue and plasma in an 
adenine-induced rat CKD model (Velenosi et al., 2016). These metabolites are also 
clinically important, for example, hippurate has been shown to accumulate in human 
ESRD (Rhee et al., 2010), and reduced hippurate or p-cresyl sulfate clearance has 
been linked to mortality risk, independent of eGFR (Suchy-Dicey et al., 2016). 
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Figure 16. Hippurate and benzoate urine concentrations, normalised to urine creatinine 
concentration, in 5/6 nephrectomy (Nx) and sham-operated rats. Reproduced with permission 
(Hanifa et al., 2019). Copyright (2019) Springer Nature.  
Dimethylglycine (DMG), betaine (trimethylglycine) and sarcosine (N-
methylglycine) are all dietary choline derivatives (McGregor et al., 2001). We found 
increased concentrations of these metabolites in 5/6 nephrectomy tissues, although 
only DMG increases were statistically significant. DMG is produced when betaine is 
used as a methyl donor in the methylation cycle, for example to convert homocysteine 
to methionine (Bertolo and McBreairty, 2013). DMG is also a known uremic 
retention solute and has been mentioned in several CKD articles, for example, 
McGregor et al. linked DMG and homocysteine concentrations in CKD (McGregor 
et al., 2001). DMG was also elevated in the study by Rhee et al. looking at patients 
with ESRD (Rhee et al., 2010); and in the study by Mutsaers et al., both DMG and 
betaine were elevated in the plasma of patients with stage 3 and 4 CKD (Mutsaers et 
al., 2013). In a contradictory finding to ours, betaine was decreased in 5/6 
nephrectomy rat kidneys (Zhong et al., 2012), and in another paper, plasma betaine 
decreased with CKD stage in humans, and both betaine and choline increased 
significantly after renal transplantation (Missailidis et al., 2016). The picture is 
complex, and although the dietary sources are important, the links to homocysteine 
metabolism and creatine metabolism via one-carbon metabolism are also important, 
and are discussed in detail in section 4.1.7.2 below. 
Other metabolites absorbed via the gut include dimethylsulfone (DMSO2), 
trimethylamine (TMA), trimethylamine oxide (TMAO), dimethylamine and 
trigonelline. The sources of these metabolites include both the diet and bacterial 
Benzoate
Hippurate
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metabolism (Engelke et al., 2005, Winning et al., 2009, Zhang, A. Q. et al., 1999). 
DMSO2 concentrations were slightly higher in 5/6 nephrectomy serum in our CKD 
model, though these differences were not statistically significant, and we found 
higher TMA levels in the 5/6 nephrectomy kidney and spleen. TMAO could not be 
quantified in serum or tissues due to peak overlap, but dimethylamine, a metabolite 
of TMAO, had higher concentrations in 5/6 nephrectomy heart and spleen tissues. 
Mutsaers et al. measured DMSO2 in humans with CKD, and demonstrated higher 
concentrations in plasma compared to controls, and they also reported the negative 
effects of DMSO2 on kidney proximal tubule cells (Mutsaers et al., 2013). Many other 
articles have found that TMA or TMAO accumulate in CKD (Bain et al., 2006, Bell 
et al., 1991, Fujiwara et al., 2009, Kim et al., 2014, Missailidis et al., 2016, Rhee et 
al., 2013). Trigonelline, a metabolite of dietary niacin, had higher concentrations in 
kidney and liver tissues, and it has also been discussed as a potential biomarker of 
human CKD (Kimura et al., 2016). 
To sum up, the diet and bacteria living in the gut are hugely important sources of 
metabolites for humans. Many of these metabolites are useful nutrients, whilst others 
are harmful, and the role of the gut in diverse diseases is being slowly uncovered. 
Tubular secretion, as opposed to glomerular filtration, is the main transport 
mechanism for these metabolites in the kidney, because of protein binding. Dietary 
changes may be the easiest way to alter the concentration of these metabolites, and 
this will be discussed further in section 4.1.8. 
 
4.1.4. ACID-BASE BALANCE 
CKD and 5/6 nephrectomy are known to eventually cause metabolic acidosis (Gadola 
et al., 2004, Maddox et al., 1986). This is partly due to the limit of nephrons to excrete 
protons in the form of ammonium (Simpson, 1971). One of the first hypotheses to 
suggest that adaptation to CKD and a reduced number of nephrons could cause long-
term problems, even whilst solving the short-term lack of nephrons, was the "intact 
nephron hypothesis” (Bricker et al., 1960, Platt, 1952). Increased ammoniagenesis in 
the remaining nephrons is thought to help maintain acid excretion, but is also thought 
to trigger tubulointerstitial injury, which eventually leads to further loss of nephrons 
(Nath et al., 1985). 
Acid-base balance is also maintained by reabsorbing filtered base, or base-
equivalents. For example, the kidneys play an important role in reabsorbing 
bicarbonate and maintaining serum concentrations, and this function is known to 
decrease in the later stages of CKD. Citrate is the most abundant organic anion in 
urine, and its reabsorption has an important role in maintaining acid-base balance 
(Curthoys and Moe, 2014, Unwin et al., 2004). In our experiment, citrate was not 
significantly affected in urine and we could not quantify citrate in tissues, probably 
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due to loss during the extraction process. Serum citrate concentrations, however, 
were significantly higher in 5/6 nephrectomy rats, potentially indicating base 
reclamation to counter metabolic acidosis. Other studies using the 5/6 nephrectomy 
rat have also found higher levels of citrate in blood (Kim et al., 2014). In humans, 
blood citrate concentrations were also higher in haemodialysis and peritoneal dialysis 
patients compared to controls (Choi et al., 2011); and higher in patients with mild 
CKD in comparison to both patients with moderate-severe CKD and healthy controls 
(Marangella et al., 1991). An article looking at human urine found lower citrate 
integrals in urine of patients with stage 3-5 CKD compared to healthy controls, which 
also fits the acid-base role (Posada-Ayala et al., 2014). 
Acid-base changes are difficult to monitor, because the body has an extremely large 
capacity to buffer changes. This means that serum bicarbonate levels (the current 
method used to assess acid-base balance in conjunction with pH) may be normal until 
late CKD. Extensive research is being carried out into early treatment of acid-base 
imbalance, and the possible role of treatment in slowing progression. For example, 
Wesson et al. have shown that although 2/3 nephrectomised rats (as opposed to the 
5/6 nephrectomy we performed) have a progressive GFR loss and a high tissue acid 
content, the changes could be ameliorated by dietary alkali (Wesson and Simoni, 
2009, Wesson et al., 2017). Gadola et al. have treated 5/6 nephrectomy rats with 
citrate, which resulted in a better inulin clearance and lower proteinuria (Gadola et 
al., 2004). There is also increasing evidence for the treatment of acidosis (or acid-
retention without overt acidosis) in humans, for example, treatment with citrate for 
two years led to a slower GFR decline (Phisitkul et al., 2010), whilst treatment with 
bicarbonate for two years slowed the rate of progression and improved nutritional 
status (de Brito-Ashurst et al., 2009). Even early (stage 2) CKD in humans may be 
associated with acid retention, suggesting the potential benefit of early treatment 
(Wesson et al., 2011). 
The key to successful treatment of acid retention in CKD would be a straightforward 
diagnostic test, and urine citrate excretion has recently been suggested to be just such 
a test. Because citrate reabsorption in the kidney is equivalent to base gain, Goraya 
et al. hypothesised that citrate excretion in urine after a dose of bicarbonate would be 
different in patients with CKD retaining acid. In their experiments they confirmed 
that patients with stage 2 CKD had a higher estimated acid retention than those with 
stage 1 CKD, and that the estimated acid retention improved after a change to a more 
base-producing diet (Goraya et al., 2019). 
Other organic anions such as oxoglutarate (alpha-ketoglutarate) and succinate also 
have a role in acid-base balance, as excretion has been shown to change in response 
to acid-producing and base-producing diets (Packer et al., 1995). NaDC-1 is the 
sodium dependent dicarboxylic acid cotransporter, and its preferred substrates 
include citrate, succinate, fumarate and oxoglutarate (Curthoys and Moe, 2014). In 
our experiments, urine concentrations of many of these organic anions were affected. 
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Oxoglutarate dropped significantly in the 5/6 nephrectomy rats, although sham-
operated rat urine concentrations were decreasing throughout the experiment, and 
there was a similar picture for fumarate and malate, but not succinate. Changes were 
still occurring in the sham-operated rats at the end of the experiment, and it is possible 
that they would eventually match the 5/6 nephrectomy urine concentrations. 
Oxoglutarate, fumarate and malate, but not succinate or citrate, were also associated 
with mortality in the study by Hu et al., discussed earlier in relation to allantoin (Hu 
et al., 2018). 
Acid-base balance also involves many other different metabolites, for example, 
glutamine is used in the kidneys to generate ammonium ions and excrete acid (Nath 
et al., 1985). In our study we found 5/6 nephrectomy rats had higher glutamine 
concentrations in kidney tissue, and lower concentrations in serum, compared to 
sham-operated rats, although neither finding was statistically significant. Glutamine 
was also associated with mortality in the study by Hu et al. (2018). Whether or not 
these changes are a part of acid-base balance remains to be seen, but the response of 
glutamine to dietary acid-base intervention would be interesting. 
To summarise, acid-base balance is a very complex homeostatic mechanism, 
involving multiple organs and many different metabolites. Current measures of acid-
base balance in arterial blood may not be able to assess buffering systems and tissue 
acid levels adequately. Even early CKD is associated with acid-base changes, and it 
may be possible to use urine metabolites to assess this, and to guide treatment. 
 
4.1.5. CREATINE AND ENERGY METABOLITES 
Creatine concentrations were lower in 5/6 nephrectomy rats in serum and tissue, 
being especially pronounced in the liver where creatine is generated. The creatine-
phosphocreatine system is an important energy buffer in the cell, used to replenish 
ATP supplies (Wallimann et al., 1992), and lower muscle mass in 5/6 nephrectomy 
rats could partly be responsible for these differences, as muscle contains most of the 
creatine in the body. However, concentrations of guanidinoacetate (GAA), the 
precursor for creatine, were not altered in kidney tissue, suggesting that the problem 
was located in the liver where GAA is converted to creatine (methyl-GAA). This step 
is also a part of one-carbon metabolism and consumes a large proportion of all the 
methyl groups used in the body, suggesting that methylation in the liver could be 
disturbed in CKD (Brosnan et al., 2011). One-carbon metabolism is discussed further 
in section 4.1.7.2 below.  
There was an interesting strong negative correlation between creatine and allantoin 
in several tissues, and between creatine and urea, creatine and creatinine, and creatine 
and allantoin in serum. This suggests that there could be a higher rate of creatine 
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breakdown, in a similar fate to purine degradation. Other studies have reported 
creatine changes, for example, in a study by Yu et al. on humans without CKD at 
entry to the study, serum creatine concentrations correlated with eGFR, although 
potential causes were not discussed (Yu et al., 2014). In another 5/6 nephrectomy rat 
study, creatine was found to be lower in kidney tissue, and this change was effectively 
prevented by a herbal treatment (Zhong et al., 2012). In a rat model of diabetic 
nephropathy caused by streptozotocin, creatine levels were also reduced in kidney 
extracts and urine, and many possible causes were listed (Zhao et al., 2011). Creatine 
concentration changes have been implicated in a wide range of diseases, and organ 
changes have led to suggestions for creatine supplementation, but without knowing 
why creatine levels are reduced, or the mechanisms linking creatine and allantoin 
concentrations, it is difficult to recommend before further research is carried out. 
The citric acid cycle intermediates, citrate, fumarate, and oxoglutarate have been 
discussed above in relation to acid-base balance, and although citric acid cycle 
changes could have been a potential cause, we found no significant changes in tissue 
succinate, fumarate, glucose, lactate or 3-hydroxybutyrate. Carnitine is an important 
transport molecule that is needed to move long chain fatty acids into the 
mitochondria, where they can be converted into acetyl coenzyme A and enter the 
citric acid cycle. Carnitine levels tended to be lower in 5/6 nephrectomy lung and 
heart tissues, but this was not statistically significant. Multiple papers have found 
carnitine or acyl-carnitines to be affected by CKD, which could suggest 
mitochondrial dysfunction (Goek et al., 2012, Rhee et al., 2010, Velenosi et al., 
2016). 
Many metabolites involved in energetic processes are affected by CKD, although the 
picture is complicated by other pathways that also involve these metabolites. 
Evidence is accumulating that creatine and carnitine metabolites are altered in blood 
and tissues, but whether this causes CKD, or is an effect of CKD, remains to be seen. 
 
4.1.6. OTHER SIGNIFICANT METABOLITES 
Asparagine was significantly higher in 5/6 nephrectomy kidneys, with no changes in 
tissue and serum. There are only a few papers that mention asparagine in relation to 
CKD, for example, melamine and cyanuric acid renal toxicity resulted in increased 
asparagine concentrations in the medulla (Kim et al., 2012). Our findings could be 
spurious, but would probably be worth further investigation. 
Myo-inositol, which is a known uremic retention solute, was not affected in tissues 
but was significantly higher in 5/6 nephrectomy serum. This is slightly surprising 
considering its role in osmoregulation in the kidney, and in contrast to allantoin and 
DMG, which both had increased serum and tissue concentrations. Other articles have 
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shown significant myo-inositol concentration changes in kidney tissue in animal 
models (Zhao et al., 2011, Zhong et al., 2012), and in blood from patients with CKD 
(Mutsaers et al., 2013, Rhee et al., 2013). 
 
4.1.7. INTERACTIONS BETWEEN METABOLITE PATHWAYS 
Although it is tempting to take each pathway discussed above individually, the 
mechanisms are probably more complex than they initially appear. There are many 
potential reasons, for example: different reactions may be located in different parts 
of the cell or in different organs, therefore requiring transport mechanisms; there are 
numerous feedback loops; and there are interactions between the different pathways. 
In addition, several metabolites have multiple roles. Some of these issues are 
discussed below. 
 
4.1.7.1 Acid-Base Connections to the Diet and Gut 
Many of the gut-derived uremic retention solutes, such as indoxyl sulfate, p-cresyl 
sulfate, kynurenine and hippurate are excreted via organic anion transporters (OATs), 
which are also involved in acid-base regulation via the transport of organic anions 
such as citrate (Nigam et al., 2015). And indoxyl sulfate, which is transported by 
OAT1 into the tubular cells of the kidney, has been shown to accumulate in and 
damage these cells, further disturbing the acid-base regulatory ability of the kidney 
(Enomoto and Niwa, 2007). Another interesting aspect of the OAT family of 
transporters is that they are widely distributed in the body, and it is hypothesised that 
they could act as a sensing and signalling network between organs via the metabolites 
they transport (this is discussed further in section 4.1.7.3 below). 
As mentioned earlier, diet is an important factor in acid-base balance, and has been 
under investigation for decades. For example, base-producing diets led to increasing 
excretion of citrate, oxoglutarate and succinate in rats in a paper from 1995 (Packer 
et al., 1995). Although the relationship between diet and CKD has been extensively 
investigated, mostly in relation to dietary protein, there has been a renewed interest 
in dietary acid and long-term outcomes in CKD. For example, higher dietary acid 
loads were associated with an increased risk of ESRD in a human population with 
CKD, and especially in those with albuminuria (Banerjee et al., 2015). Oral treatment 
with bicarbonate or citrate has been shown to slow the progression of CKD (de Brito-
Ashurst et al., 2009, Gadola et al., 2004, Phisitkul et al., 2010), and in the absence of 
overt metabolic acidosis, as measured in arterial blood gas analysis, the mechanisms 
probably include acid retention in tissues (Wesson and Simoni, 2009, Wesson et al., 
2017). 
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Difficulties remain in measuring acid retention, or dietary acid load, and without a 
straightforward test it will be difficult to assess the clinical significance of acid 
retention, or the effect of dietary modification. Research is being carried out on a 
potential test, and there have been promising trials showing that increasing base 
intake with extra fruit and vegetables can slow the decline of kidney function (Goraya 
et al., 2014, Goraya et al., 2019). 
 
4.1.7.2 One-Carbon Metabolism 
 
Figure 17. Pathways linked to one-carbon metabolism. S-Adenosylmethionine (SAM) is an 
important methyl donor, which is converted to S-adenosylhomocysteine (SAH) during methyl 
donation. SAM can be (re)generated in multiple ways, using different metabolites. 
THF, tetrahydrofolate; DHF, dihydrofolate; DMG, dimethylglycine, Met, methionine; 
Hcy, homocysteine; GSH, glutathione. Adapted from (Dahlhoff et al., 2013) under the Creative 
Commons BY 4.0 license. Copyright (2013) Dahlhoff et al., 
(https://doi.org/10.1371/journal.pone.0057387.g001). 
One-carbon units are required in many synthetic pathways, for example, carnitine, 
creatine, amino acid, and phosphatidylcholine synthesis; and of course DNA, RNA 
and protein methylation (Bertolo and McBreairty, 2013). One of the key enzymes 
involved is betaine homocysteine methyltransferase (BHMT), which is particularly 
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active in the kidney and liver. The sources of methyl groups include methionine, 
folate, betaine and choline, which are used to generate S-adenosylmethionine (SAM) 
in the methylation cycle (Figure 17). The wide range of reactions requiring 
methylation, and the large amount used for creatine synthesis, could suggest that 
competition for methyl groups can have effects on multiple pathways, especially in 
the liver where the creatine precursor is methylated. As discussed above, creatine 
concentrations were lower in serum and tissues in 5/6 nephrectomy rats, and the 
serum findings are in agreement with a human study, which found serum creatine 
correlated with eGFR (Yu et al., 2014).  
The knock-on effect on other metabolites could include dimethylglycine (DMG), 
betaine and sarcosine levels, with important medical implications. For example, the 
plasma levels of DMG, which is produced when betaine has donated its methyl group, 
were elevated and correlated with homocysteine levels in human CKD (McGregor et 
al., 2001). Yu et al. found that serum concentrations of carnitine and betaine, as well 
as the creatine levels discussed earlier, correlated with eGFR (Yu et al., 2014). 
Consequences include the link between plasma DMG and risk of acute myocardial 
infarction, which was reported to be independent of traditional risk factors (Svingen 
et al., 2013). Lastly, there have been many attempts to reduce homocysteine levels to 
reduce cardiovascular disease, but these have not been successful, suggesting that 
other one-carbon sources are also important or that homocysteine concentrations are 
not a causal factor (Martí-Carvajal et al., 2017). 
 
4.1.7.3 Remote Sensing and Signalling 
As mentioned above, the OAT family of transporters has been hypothesised to be 
part of an inter-organ network which enables metabolism to be coordinated across 
the entire body. This “remote sensing and signalling” hypothesis was developed as 
the complexity of the SLC22 transporter family (which includes the OAT and OCT 
transporter families) was being discovered. The key points of this hypothesis are that 
the transporters are present on multiple organs and that they have overlapping 
substrate specificities, some of which are important rate-limiting metabolites (Ahn 
and Nigam, 2009). This hypothesis could explain crosstalk between organs, such as 
the cardiovascular effects of chronic kidney disease; the effect of the gut microbiome 
on the kidney and other organs; and the interaction between uremic retention solutes 
and other metabolites. Substrates that have been implicated in these interactions 
include known uremic toxins such as indoxyl sulfate, and also key metabolic 
intermediates (Ahn and Nigam, 2009, Wikoff et al., 2011). 
In a similar fashion to the OAT substrates, it has been suggested that other 
metabolites are also remote sensing intermediates. For example, oxoglutarate is a key 
cofactor for the 2-oxoglutarate (alpha-ketoglutarate) dependent dioxygenases (2-
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OGDO), which have a wide range of functions in the body. These enzymes are 
controlled by the availability of oxoglutarate, oxygen and iron, and given that 
oxoglutarate is an intermediate of the citric acid cycle, it has been postulated that 
these enzymes are sensitive to changes in energy metabolism (Salminen et al., 2015). 
 
4.1.8. NEW TREATMENT OPTIONS 
Although the main focus of this work is diagnosis, some of the metabolic pathways 
discussed above could suggest potential treatment options. Dietary interventions can 
be simple and effective, and especially in the case of acid retention discussed above, 
evidence is accumulating for treatment with citrate, bicarbonate or a base-producing 
diet earlier than is currently recommended (Goraya et al., 2014). More evidence is 
needed before this becomes accepted practice, and also a validated diagnostic test for 
acid retention, but it is not difficult to recommend eating more fruit and vegetables. 
Because of the link between CKD and uric acid concentrations, xanthine oxidase 
inhibitors such as allopurinol have been suggested to be useful. Small-scale trials 
have had positive results (Goicoechea et al., 2010, Siu et al., 2006), and large-scale 
trials are underway (Maahs et al., 2013). Weight loss and calorie restriction can help 
patients with gout to lower uric acid concentrations (Dessein et al., 2000), and calorie 
restriction could help renal outcomes in patients with obesity and diabetes 
(Ruggenenti et al., 2017). 
The gut microbiota has been implicated as a source of uremic toxins, and it is 
receiving more and more attention for its role in many diseases. But although it is an 
accessible target for treatment, changing the gut microbiota is difficult, for example 
needing an extensive and long-term change of diet, or transplantation. Other options 
include binding metabolites in the gut using adsorbents, such as AST-120, or 
targeting bacterial species or specific pathways with drugs (Zhang and Davies, 2016). 
Even intermittent fasting and calorie restriction could have positive effects by 
modifying the gut microbiome (Li et al., 2017). 
Finally, the ability to measure more uremic toxins, and especially those which 
represent tubular function, could help to compare the effectiveness of different 
dialysis modalities, improve dialysis methods, and eventually, permit more 
personalised dialysis and treatment.  
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4.1.9. STRENGTHS AND LIMITATIONS 
Perhaps the most unique part of this work is that multiple tissues were analysed 
together with serum and urine. This helps us in several ways, such as providing some 
evidence for the origin of the metabolites, the mechanisms of inter-organ crosstalk, 
and whether urine and serum can reflect organ processes. 
Although we originally thought that we could use metabolomics to describe the 5/6 
nephrectomy model, we realised that time constraints and limited coverage would 
mean that a full characterisation was not possible. Ideally, we would have followed 
the rats until death, and analysed blood, urine and tissue at various points along the 
trajectory. This would have enabled a better organ localisation of the origin of the 
significant metabolites, as well as enabling us to differentiate which metabolites were 
important in different stages of CKD. Following the rats until death would also have 
allowed us to compare the ageing profiles of 5/6 nephrectomy and sham-operated 
rats, which is one of the theories of CKD. 
Although we have attempted to put the individual metabolites into the context of 
biochemical pathways, this is difficult because of the sparse coverage of these 
pathways. In addition, the cause of increased metabolite concentrations is difficult to 
tease apart from the effects of reduced removal after 5/6 nephrectomy. Also, the 
complex web of metabolite pathways, and the crosstalk between organs adds another 
layer of complexity. 
Animal models cannot fully represent human disease, partly because of metabolic 
differences, for example, humans do not possess the uricase enzyme to convert uric 
acid into allantoin. Although this could mean that our findings in rats are not 
applicable to humans, research in humans has also found some of the same metabolite 
changes, including increased allantoin concentrations, in CKD. Another difference 
between animal models and human disease, is that human diseases are generally 
multifactorial. This simplification, however, makes animal research easier and 
requires less subjects, because of reduced genetic and environmental variation. 
Statistical power is another limitation in this work, and larger numbers in each group 
could have helped to find more significant metabolites. This experiment was, 
however, set up as a hypothesis generating approach, and we hope that the 
metabolites found in this study can be explored further. 
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4.1.10. FUTURE WORK 
Other sources of information, such as proteomics or transcriptomics, would be 
extremely helpful in pinning down pathways for investigation or even treatment 
targets. Genomics may also help to find out why different patients can have such 
different outcomes. Another way of improving metabolite coverage would be to use 
other chemical analysis methods, such as mass spectrometry, which could also 
validate the NMR findings whilst simultaneously providing more information for 
metabolite identification. Other analytical methods that could be used to probe 
specific pathways include labelling of metabolites, such as isotopic labelling (e.g. 14C 
labelling), or hyperpolarisation. Hyperpolarisation is a relatively new technique that 
increases the signal of NMR-sensitive nuclei, and it has already been used to create 
labelled metabolites that can be followed using magnetic resonance spectroscopy 
(MRS) in vivo (Mikkelsen et al., 2017, Zacharias et al., 2012). 
However, it is clear that CKD in humans is a complex disease process, with complex 
causes, and complex multi-organ results. There is probably no single pathway or 
single biomarker that can be used to diagnose or explain the diverse facets of the 
disease. One way forward would be to try and subcategorise CKD using these 
metabolites, along with clinical information. For example, it seems reasonable that 
CKD secondary to diabetes could result in a different biomarker profile to CKD 
secondary to high blood pressure (Kimura et al., 2016), but it could also be possible 
to subcategorise by gut flora phenotype. It is also important to consider the statistical 
models, which are not able to fully accommodate the complex multi-factorial nature 
of human disease. More work needs to be done to develop these statistical models 
and make them easy to use (Ghezzi et al., 2018). 
Finally, chemical shifts in urine also contain valuable information, for example it is 
well known that metabolite peaks in NMR spectra of urine move in response to 
differing pH and ion concentrations. This has led to difficulty in analysing urine with 
NMR, and attempts to control the matrix with different buffers. In more recent work, 
the pH and NMR-invisible ion concentrations’ effects on chemical shift have been 
explored, resulting in the possibility to estimate these concentrations via the chemical 
shift of NMR-visible metabolites. In the future, this could be an extremely powerful 
method to analyse urine using NMR (Takis et al., 2017, Tredwell et al., 2016). 
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4.2. PAPER II – CITRATE NMR PEAK IRREPRODUCIBILITY IN 
BLOOD SAMPLES AFTER REACQUISITION OF SPECTRA 
During the serum analyses of the 5/6 nephrectomy paper, a number of serum spectra 
had to be reanalysed, normally because of lineshape problems which required 
repeated shimming, but also for routine reanalysis before two-dimensional spectra 
were acquired. On a few occasions we noticed that some metabolite integrals, and in 
particular the citrate signals, had a different intensity in the repeated NMR spectrum. 
Therefore, in this paper we attempted to describe the changes in citrate, lactate, 
glucose, phenylalanine and histidine peak integrals in NMR spectra from serum and 
plasma samples subjected to repeated NMR acquisition. Two parts of this work are 
important, firstly, there are general issues surrounding integration of peaks and 
quantification of metabolites, which affect all metabolomics studies. Secondly, peak 
integrals were occasionally different in the repeated NMR spectra, which could have 
important consequences.  
 
4.2.1. SUMMARY OF RESULTS 
With regards to general integration issues, two peaks for each metabolite were 
integrated to check precision in this study, and although all serum integral 
correlations (Inta vs Intb) were reasonable (citrate and lactate R2 > 0.98; glucose R2 = 
0.85; phenylalanine and histidine R2 ≥ 0.70), the corresponding correlations of 
percentage changes (ΔInta(%) vs ΔIntb(%)) were not as good (citrate R2 = 0.93; 
lactate R2 = 0.66, glucose R2 = 0.23; phenylalanine R2 = 0.30; histidine R2 = 0.05). 
Plasma peak integral correlations (Inta vs Intb) were generally worse than serum 
(citrate R2 = 0.83; lactate, glucose and histidine R2 > 0.95; phenylalanine R2 = 0.58), 
and the correlations of percentage changes (ΔInta(%) vs ΔIntb(%)) were very weak 
(all R2 ≤ 0.13; with citrate and histidine R2 ≤ 0.02). 
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Figure 18. (A) Serum citrate peak integral correlation (Inta vs Intb). (B) Serum citrate 
correlation of peak integral differences (ΔInta(%) vs ΔIntb(%)) after reanalysis. (C) Plasma 
peak integral correlation (Inta vs Intb). (D) Plasma citrate correlation of peak integral 
differences (ΔInta(%) vs ΔIntb(%)) after reanalysis. Reproduced with permission (Hanifa et al., 
2019). Copyright (2019) Springer Nature.  
With regards to changes in the repeated spectra, although most repeated acquisitions 
were not significantly different, there was a clear and consistent difference in citrate 
peaks in a few serum spectra. Out of 44 repeated serum samples, 11 spectra had a 
significant citrate percentage reduction (≤ -5%), whilst 4 samples had a significant 
percentage increase (≥ +5%). Serum lactate and glucose peak integrals were larger in 
a small minority of these spectra, and there were no consistent changes in plasma 
samples for lactate or glucose. In plasma, because of the close proximity of the large 
EDTA peaks, and other overlapping peaks, accurate integration of the small citrate 
peaks was difficult, and no clear pattern could be discerned. There was a clear 
decrease in the lipoprotein signal in both repeated serum and plasma samples, 
however, this loss did not correlate with changes in the other signals. The lower 
intensity phenylalanine and histidine peaks were also investigated, and there was no 
clear pattern in the change of either, though issues with the signal-to-noise ratio may 
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4.2.2. CITRATE PEAK INTEGRAL CHANGES 
Although citrate binding to protein has been discussed in the literature, the changes 
occurring when NMR spectral acquisition has to be repeated have not been 
previously reported. Although only a small number of samples have to be repeated, 
and only a small minority of these suffer problems, it could lead to misinterpretation 
of results. Perhaps the biggest problem is that the timing of these changes after sample 
collection is unknown, and that these changes may have already taken place before 
the first NMR acquisition. Citrate is a key metabolite in the citric acid cycle and in 
acid-base balance in the kidney. In metabolomics studies, changes in blood 
concentrations are often suggested to imply citric acid cycle problems, and citrate 
was also a significant metabolite in the other papers in this thesis. 
We were not, however, able to identify the cause of these changes. Other groups have 
described NMR invisible fractions of metabolites such as citrate, lactate, 
phenylalanine and histidine (Bell et al., 1988, Nicholson and Gartland, 1989). 
Possible causes of the bound proportion changing include external factors, such as 
heating and cooling during NMR measurement, and internal factors, for example it 
is possible that enzymes are still present and active. Methods for reducing this 
binding include using ammonium chloride, sodium chloride, SDS, perchloric acid 
and higher temperatures (Bell et al., 1988); whilst Nicholson and Gartland (1989) 
found that acidification reduced binding. 
As mentioned in paper II, there is also the possibility that different metabolites 
compete for binding sites. For example, addition of fatty acids, or citrate, to a mixture 
of metabolites and human serum albumin has been shown to release some of the 
bound metabolites from albumin (Jupin et al., 2013). In a similar manner, TSP has 
been shown to release bound metabolites, including isoleucine, leucine and 
phenylalanine, in human plasma samples (Barrilero et al., 2017). TSP was part of the 
buffer in paper I, whilst DSA was used in the human serum samples in paper II, and 
no internal reference was used in the human plasma in paper II or the serum samples 
in paper III. Even dilution has been shown to change the fraction of metabolite bound 
to protein (Barrilero et al., 2017, Jupin et al., 2014). 
However, none of the articles discussed above can explain why changes occurred 
after the first NMR acquisition, when temperature changes were minimal and nothing 
was added to the sample. Only one article, to the best of our knowledge, has discussed 
changes over time, reporting decreased lipoprotein signal intensity after 24 hours 
(Dona et al., 2014). This change was partially reversed by mixing the sample, and the 
authors suggested that settling of lipoproteins below the active region of the NMR 
coils was responsible. We also found a lipoprotein signal loss in the repeated spectra, 
but this did not correlate with the citrate changes. 
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4.2.3. METHODOLOGICAL ISSUES 
The technical side of reproducibility is an important factor, and is often overlooked 
in metabolomics articles. Although NMR is generally regarded as more reproducible 
but less sensitive than MS, it is difficult to quantify overlapping NMR peaks 
accurately. We found this to be a problem when analysing the small citrate signals 
sitting on the large EDTA peaks in the plasma samples. Although the integrals 
correlated well (Figure 18C), the percentage changes did not (Figure 18D). 
Deconvolution, peak fitting and baseline correction are some of the methods which 
can be employed to separate overlapping peak integrals, but none are currently 
capable of the accuracy required. In addition, if human input is required, it can be 
subjective and reduce reproducibility. 
Another reason that the percentage changes did not necessarily correlate is because 
of the propagation of uncertainty. This is where the uncertainty is amplified when 
calculations are performed on measurements which have an associated imprecision. 
Formulae exist to combine or adjust these uncertainties, and always lead to a larger 
uncertainty for the result than for the original measurements (Ku, 1966). This would 
apply when dividing one metabolite concentration by another, such as when 
calculating concentrations relative to another metabolite concentration (for example 
creatinine in urine, or percentage change); and because of the smaller signal-to-noise 
ratio, this affects the smaller peaks more than the larger peaks. This was clearly seen 
in the plasma histidine graphs, where large histidine peaks in the samples from 
patients who received histidine had an excellent correlation for both peak area and 
percentage change (Figure 19A+D, peak integral R2 = 1.00, percentage change R2 = 
0.91). But although the small peaks, which were closer to the noise level, had an 
acceptable correlation (Figure 19C, R2 = 0.90), their percentage changes were not at 
all correlated (Figure 19B, R2 = 0.01). 
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Figure 19. (A) Plasma histidine peak integral correlation (Inta vs Intb). (B) Plasma histidine 
correlation of peak integral differences (ΔInta(%) vs ΔIntb(%)) after reanalysis. (C) Magnified 
plasma histidine peak integral correlation. (D) Magnified plasma histidine correlation of peak 
integral differences after reanalysis. The large histidine integrals and percentage changes 
(black) correlated well, in contrast to those with a small signal-to-noise ratio (grey). 
Reproduced with permission (Hanifa et al., 2019). Copyright (2019) Springer Nature.  
 
4.2.4. CONNECTIONS TO PAPERS I AND III 
Citrate was undetectable in the NMR spectra of rat tissue extracts in paper I, which 
could be due to co-precipitation of citrate bound to protein during the extraction 
process (Daykin et al., 2002). Citrate changes in blood in both papers I and III could 
be partly due to changes in protein binding (caused by, for example, uremic retention 
solutes, or treatment with fluids and medication), but there are also many other 
potential causes for citrate concentration changes, which are discussed in the papers. 
In connection with some of the theory dealing with causality and biomarkers, we 
should also consider whether citrate, or citrate binding, is a general marker of well-
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related (Ghezzi et al., 2018). If this is the case, it would be worth investigating in 
larger groups, for example all intensive care patients. 
Complex interactions between metabolites and proteins could also explain why most 
uremic retention solutes do not fulfil Bergstom’s criteria. There are, of course, many 
things that we cannot measure in tissues and blood, and also long-term effects of 
exposure that we cannot define or measure easily at the moment, which could 
describe uremic symptoms better. 
 
4.2.5. FUTURE WORK 
The first step would be to confirm that protein binding of citrate is the cause of the 
change, and why this changes after repeated acquisition. This could be done, for 
example, by using NMR to measure diffusion coefficients. If confirmed, it would be 
interesting to consider whether this is useful, for example, pharmaceutical modelling 
of dosing uses knowledge of protein or lipid binding, and drug interactions are 
immensely important for patient safety. NMR could be used to assess the changes in 
the proportion of bound metabolite under different conditions, for example: after 
illness, after medication, during dialysis, or even after something as simple as 
intravenous fluid administration during surgery. NMR could also be used to more 
accurately dose medicines that are strongly protein bound. As suggested in the paper, 
NMR is in a unique position to assess protein-metabolite interactions, and 
“interactive/interaction metabolomics” has been suggested as a window into this 
complexity (Daykin et al., 2012). 
Perhaps the simplest solution to accurately quantify protein bound metabolites would 
be to remove protein first, but protein removal could also lead to removal of these 
metabolites. There are, however, many different extraction and filtration methods, 
and investigating the amount of metabolite lost would be potentially useful work.  
 
4.2.6. IMPLICATIONS FOR BIOMARKER VALIDATION 
Because of the issues discussed above, and because of the lack of translation from 
laboratory to clinical use in many ‘omics’ fields, it is becoming more and more 
important to validate any biomarkers that have been discovered. Validation should 
include testing on an independent group, and not relying on internal (cross) 
validation; but validation should also include different analytical methods, or 
different sample types, or even different sample preparation techniques. These are 
necessary to avoid statistical pitfalls, but also to avoid experimental problems caused 
by the analytical methods themselves. 
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The Metabolomics Standards Initiative guidelines suggest a minimum signal-to-noise 
ratio (SNR) of 10 for quantification (Sumner et al., 2007). It may be helpful to report 
the SNR for each metabolite, and use the SNR to calculate an uncertainty for derived 
quantities, such as percentage change. It would also be useful to integrate more than 
one peak area per metabolite and evaluate the correlation, to ensure precise 
integration. 
 
4.3. PAPER III – PREDICTIVE BIOMARKERS AND METABOLIC 
HALLMARK OF POSTOPERATIVE HYPOXAEMIA 
When lung function is impaired, the exchange of oxygen and carbon dioxide through 
the lungs is compromised, which has consequences for all other organs in the body. 
One of the causes is acute respiratory distress syndrome, which occurs after an insult 
to the lungs. These insults can be very different, which suggests a multifactorial 
illness, but there seems to be some common pathological mechanisms. 
 
4.3.1. SUMMARY OF RESULTS 
 
Figure 20. Prediction of oxygenation on the third postoperative day using NMR spectra of 
blood samples taken 16 hours after the end of the operation. Reproduced with permission 
(Maltesen et al., 2016). Copyright (2016) Springer Nature.  
Out of the 47 patients where samples were available, 32 (68%) suffered hypoxaemia 
post-operatively, of which 9 (19%) suffered severe hypoxaemia, and 23 (49%) 
suffered mild hypoxaemia. As discussed in paper III, it was possible to predict 
oxygenation status three days postoperatively with NMR spectra of blood samples 
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taken 16 hours postoperatively (Figure 20). This was an interesting result, with real 
implications for clinical practice. In parallel to the CKD discussions, earlier diagnosis 
or finding patients at risk of hypoxaemia before they have the disease, would allow 
resources to be focussed on the patients that need it. This could save money, by 
allowing low risk patients to be moved from intensive care at an earlier stage, or 
enable earlier intervention in those at high risk, potentially reducing the severity of 
disease. 
Integration of the significant peaks identified a large number of different metabolites 
that were significantly different between groups, including: amino acids such as 
glycine, lysine, alanine and phenylalanine; energy intermediates such as citrate, 
pyruvate, acetate, acetoacetate, 3-hydroxybutyrate and carnitine; and lipids and 
lipoproteins. These will be summarised and discussed in the following section. 
 
Figure 21. Representative NMR spectra of serum samples taken 16 hours postoperatively 
from: one patient that did not develop hypoxaemia (black spectrum); and one patient who 
subsequently developed hypoxaemia (red spectrum). The spectral difference (unaffected – 
hypoxaemic) illustrates the scale of the changes. Reproduced with permission (Maltesen et al., 






















NMR-BASED METABOLOMICS IN KIDNEY AND LUNG DISEASE 
90 
4.3.2. SIGNIFICANT METABOLITES 
To help understand the changes that occur after surgery, and the differences between 
the three groups (severe, mild and unaffected), the significant metabolites will be 
discussed in three groups: energy intermediates, stress responses, and oxidative 
stress. These groups, however, overlap a great deal, both in terms of metabolites and 
processes. 
 
4.3.2.1 Energy Intermediates 
Important intermediates in energy metabolism include: citrate, pyruvate, lactate, 
acetate, carnitine, alanine and ketone bodies. Increased citrate, pyruvate and acetate 
concentrations in the hypoxaemic groups, especially in the left atrial (LA) samples, 
suggest that there was less consumption of these metabolites, or increased production. 
This could be because oxidative phosphorylation was limited, possibly because of a 
low PaO2, or because of increased production of intermediates from glycolysis which 
were not able to be further metabolised as quickly as they were produced (Garcia-
Alvarez et al., 2014). Citrate, however, was administered during surgery as a 
component of the cardioplegic solution used to stop the heart beating and, as 
discussed in paper II, the citrate peak in NMR spectra is also affected by protein 
binding. Therefore, citrate peak changes may reflect other processes that occurred 
during surgery, such as fluid administration. 
Other sources of energy intermediates include protein catabolism, which releases 
alanine, and alanine concentrations were higher in the hypoxaemic patients (Levy, 
2006). Ketone bodies such as acetoacetate and 3-hydroxybutyrate also had higher 
concentrations in the hypoxaemic patients. Carnitine, which is an important transport 
molecule in fatty acid metabolism to generate acetyl-CoA for the citric acid cycle, 
also had a higher concentration in the hypoxaemic groups. Different organs can use 
different metabolites as energy sources, for example, the heart is especially flexible 
and can use fatty acids, lactate and amino acids, as well as glucose, to generate ATP; 
whilst ketone bodies are important sources of energy for the brain, heart and muscle 
(Lopaschuk, 2018). When under stress, lactate can be a greater source of pyruvate 
than glucose, and the lungs are thought to be a major source of lactate during sepsis 
(Garcia-Alvarez et al., 2014). Lactate concentrations were not significantly different 
between groups, which would be expected with hypoxaemia, and therefore the 
reasons for these changes are not entirely clear, although lactate concentrations had 
probably normalised by the time blood samples were taken (on the day after surgery).  
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4.3.2.2 Stress Response to Surgery 
There were also many lipid and lipoprotein changes, including increased 
polyunsaturated fatty acids (PUFA), cholesterol and lipoproteins. Many are markers 
of cell damage and mediators of inflammation and the stress response, and could have 
been released during surgery, or during subsequent lung injury (Desborough, 2000). 
For example, free fatty acids and cholesterol were affected, potentially suggesting 
release as a result of cell membrane damage. Specific fatty acids are inflammatory 
mediators, and these could also be part of the PUFA signal increase. 
Metabolites involved in energy processes are also altered by the stress response. For 
example, epinephrine (adrenaline) stimulates lactate production and is associated 
with a positive prognosis, which suggests that it is an adaptive response (Wutrich et 
al., 2010). Alanine concentrations can also change due to protein catabolism, as 
mentioned above, which is thought to be a stress response. Activation of the pituitary-
adrenal stress response has been suggested to be mediated by the nervous system, and 
drugs that target these systems could be worth studying (Desborough, 2000). 
 
4.3.2.3 Oxidative Stress 
Oxidative stress could be considered as part of the overall stress response to surgery, 
but it has some unique metabolite features, and is generally considered separately. 
Hypoxanthine, a purine degradation metabolite of inosine or adenine, is oxidised to 
xanthine and uric acid (Figure 15 in section 4.1.2). It had a significantly lower 
concentration in the hypoxaemic group, which could suggest increased oxidative 
stress. However, the findings do not match previous publications, which have 
suggested that hypoxanthine increases after ischemia and reperfusion. Quinlan et al. 
found higher plasma concentrations in patients with ARDS, and they also found a 
significant difference in concentrations between survivors and non-survivors 
(Quinlan et al., 1997). In another paper, Evans et al. found higher concentrations of 
hypoxanthine in bronchoalveolar lavage fluid (BALF) from patients with ARDS 
(Evans et al., 2014). These differences, however, could be due to sample timing 
differences, or sample type differences. 
A major source of oxidative stress in lung injury is thought to be due to neutrophils 
and macrophages, which are cells involved in the responses to infection and 
inflammation. The role of inflammation could be extremely important, because it can 
be targeted by medication. This has led to the trial of steroids and aspirin, which 
modify the inflammatory response, and also medications such as propofol and statins, 
whose main action is not modulating inflammation, although they possess antioxidant 
or anti-inflammatory properties (Altintas et al., 2011, Balyasnikova et al., 2005). 
Unfortunately, the results of multiple trials have been disappointing, although 
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subgroup analysis has occasionally led to interesting findings (Abdulnour et al., 2018, 
Kor et al., 2016). 
Oxidative stress is a complex subject, it is very difficult to measure, and it should 
also be noted that it is extremely difficult to localise which organ the metabolic 
changes originate from. Since surgery involved stopping the heart beating, stopping 
breathing, and taking over these two processes, oxidative stress could be primarily 
located in the heart rather than the lungs, or even in other organs which are not 
receiving an adequate supply of oxygen or blood. 
 
4.3.3. CONNECTIONS TO PAPERS I AND II 
One of the links between the kidney and lung research papers is oxidative stress. As 
mentioned above, hypoxanthine concentrations were lower in patients that developed 
hypoxaemia, but hypoxanthine was not found in the 5/6 nephrectomy experiment 
(paper I), possibly due to peak overlap or peak shift. However, allantoin, which is 
further downstream in purine breakdown, was identified in paper I, but although 
allantoin has a relatively isolated signal in the NMR spectrum, it was not at all visible 
in the human blood samples. It is known that humans do not possess the enzyme to 
convert uric acid to allantoin, and this could therefore represent species differences, 
however, as discussed in paper I, it has been shown that allantoin is present in humans 
subjects, and it is presumed that this is due to oxidative stress. It could be that 
allantoin is only present at large enough concentrations in chronic oxidative states, 
rather than acute injury. Or allantoin production could require a larger concentration 
of uric acid, which itself is dependent upon the breakdown of purines. And perhaps 
a more sensitive analytical method would have been able to detect allantoin in these 
samples. 
In a similar fashion to the subdivision of patients with CKD, there seems to be a 
stratification of patients with lung injury into groups with either a high inflammatory 
status or a low inflammatory status (Calfee et al., 2014). These subgroups appear to 
be important not only for patient outcome, but also for research success (Acosta-
Herrera et al., 2014). If this can be confirmed, and testing can be performed easily 
and cheaply, it could lead to better risk stratification, more focused research, and 
better targeting of treatment. 
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4.3.4. FUTURE WORK 
Further experiments are in progress to test these findings in new datasets and other 
types of sample, for example tissue samples or bronchoalveolar fluid could prove to 
be useful to pinpoint the sources of changes. Some of these metabolites are excreted 
in urine, and it may therefore be worth investigating urine metabolites as well. 
Comparison with other endpoints, such as mortality, duration of ventilatory support, 
or length of admission may be worth investigating. As discussed previously, it may 
also be possible to subcategorise patients, and investigate metabolic differences in 
those with different levels of inflammation. In the future, it may be possible to tell 
who will mount a larger stress response or inflammatory response before surgery, 
which could allow resources to be efficiently targeted, and even preventative 









CHAPTER 5. CONCLUSIONS 
Metabolomics and other ‘omics’ fields hold great promise for understanding disease 
mechanisms, early diagnosis and monitoring treatment. There is also the possibility 
that improved understanding leads to more specific diagnoses, improved risk 
stratification, new treatment options, and even new preventative measures.  
However, there are still problems that need to be overcome and limitations to be 
understood. Large scale validation studies are needed to confirm findings, but there 
is also a need for studies that can examine relevant pathways, investigate the 
multifactorial nature of diseases, and find ways to tailor treatments to individual risk 
profiles. 
Dealing with uncertainty is difficult, and the ‘omics’ fields come with plenty of 
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